Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
29 "Ho Yeong Lim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Gastrointestinal cancer
A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer
Hyunji Jo, Seung Tae Kim, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Jeong Il Yu, Hee Chul Park, Doo Ho Choi, Yoonah Park, Yong Beom Cho, Jung Wook Huh, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Won Ki Kang
Cancer Res Treat. 2023;55(1):189-195.   Published online June 8, 2022
DOI: https://doi.org/10.4143/crt.2021.1527
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this phase II trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, to preoperative chemoradiotherapy (CRT) with capecitabine confers a clinical benefit to patients with locally advanced rectal cancer (LARC).
Materials and Methods
Patients with LARC (defined by clinical stage T3/4 and/or lymph node positivity) received preoperative radiation (45-50.4 Gy in 25-28 daily fractions) with concomitant capecitabine (825 mg/m2 twice per day) and simvastatin (80 mg, daily). Curative surgery was planned 4-8 weeks after completion of the CRT regimen. The primary endpoint was pathologic complete response (pCR). The secondary endpoints included sphincter-sparing surgery, R0 resection, disease-free survival, overall survival, the pattern of failure, and toxicity.
Results
Between October 2014 and July 2017, 61 patients were enrolled; 53 patients completed CRT regimen and underwent total mesorectal excision. The pCR rate was 18.9% (n=10) by per-protocol analysis. Sphincter-sparing surgery was performed in 51 patients (96.2%). R0 resection was achieved in 51 patients (96.2%). One patient experienced grade 3 liver enzyme elevation. No patient experienced additional toxicity caused by simvastatin.
Conclusion
The combination of 80 mg simvastatin with CRT and capecitabine did not improve pCR in patients with LARC, although it did not increase toxicity.

Citations

Citations to this article as recorded by  
  • Effects of Hyperlipidemia on Osseointegration of Dental Implants and Its Strategies
    Haiyang Sun, Shuhuai Meng, Junyu Chen, Qianbing Wan
    Journal of Functional Biomaterials.2023; 14(4): 194.     CrossRef
  • 5,706 View
  • 165 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer
Gyu Sang Yoo, Hee Chul Park, Jeong Il Yu, Doo Ho Choi, Won Kyung Cho, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Woo Yong Lee, Hee Cheol Kim, Seong Hyeon Yun, Yong Beom Cho, Yoon Ah Park, Kyoung Doo Song, Seok-Hyung Kim, Sang Yun Ha
Cancer Res Treat. 2020;52(2):446-454.   Published online September 25, 2019
DOI: https://doi.org/10.4143/crt.2019.261
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the role of carcinoembryonic antigen (CEA) levels in improving the performance of magnetic resonance imaging (MRI) for the prediction of pathologic response after the neoadjuvant chemoradiation (NCRT) for patients with rectal cancer.
Materials and Methods
We retrospectively reviewed the medical records of 524 rectal cancer patients who underwent NCRT and total mesorectal excision between January 2009 and December 2014. The performances of MRI with or without CEA parameters (initial CEA and CEA dynamics) for prediction of pathologic tumor response grade (pTRG) were compared by receiver-operating characteristic analysis with DeLong’s method. Cox regression was used to identify the independent factors associated to pTRG and disease-free survival (DFS) after NCRT.
Results
The median follow-up was 64.0 months (range, 3.0 to 113.0 months). On multivariate analysis, poor tumor regression grade on MRI (mrTRG; p < 0.001), initial CEA (p < 0.001) and the mesorectal fascia involvement on MRI before NCRT (mrMFI; p=0.054) showed association with poor pTRG. The mrTRG plus CEA parameters showed significantly improved performances in the prediction of pTRG than mrTRG alone. All of mrTRG, mrMFI, and initial CEA were also identified as independent factors associated with DFS. The initial CEA further discriminated DFS in the subgroups with good mrTRG or that without mrMFI.
Conclusion
The CEA parameters significantly improved the performance of MRI in the prediction of pTRG after NCRT for patients with rectal cancer. The DFS was further discriminated by initial CEA level in the groups with favorable MRI parameters.

Citations

Citations to this article as recorded by  
  • Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement
    Jeong Ha Lee, Nalee Kim, Jeong Il Yu, Gyu Sang Yoo, Hee Chul Park, Woo-Yong Lee, Seong Hyeon Yun, Hee Cheol Kim, Yong Beom Cho, Jung Wook Huh, Yoon Ah Park, Jung Kyong Shin, Joon Oh Park, Seung Tae Kim, Young Suk Park, Jeeyun Lee, Won Ki Kang
    Radiation Oncology Journal.2024; 42(2): 130.     CrossRef
  • Predicting the response to neoadjuvant chemoradiation for rectal cancer using nomograms based on MRI tumour regression grade
    S. Qin, Y. Chen, K. Liu, Y. Li, Y. Zhou, W. Zhao, P. Xin, Q. Wang, S. Lu, H. Wang, N. Lang
    Cancer/Radiothérapie.2024; 28(4): 341.     CrossRef
  • Body composition parameters combined with blood biomarkers and magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
    Jianguo Yang, Qican Deng, Zhenzhou Chen, Yajun Chen, Zhongxue Fu
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Pretreatment blood biomarkers combined with magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
    Xinyu Shi, Min Zhao, Bo Shi, Guoliang Chen, Huihui Yao, Junjie Chen, Daiwei Wan, Wen Gu, Songbing He
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical implication and management of rectal cancer with clinically suspicious lateral pelvic lymph node metastasis: A radiation oncologist’s perspective
    Gyu Sang Yoo, Hee Chul Park, Jeong Il Yu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • High-Resolution T2-Weighted MRI to Evaluate Rectal Cancer: Why Variations Matter
    Kirsten L Gormly
    Korean Journal of Radiology.2021; 22(9): 1475.     CrossRef
  • MRI Assessment of Complete Response to Preoperative Chemoradiation Therapy for Rectal Cancer: 2020 Guide for Practice from the Korean Society of Abdominal Radiology
    Seong Ho Park, Seung Hyun Cho, Sang Hyun Choi, Jong Keon Jang, Min Ju Kim, Seung Ho Kim, Joon Seok Lim, Sung Kyoung Moon, Ji Hoon Park, Nieun Seo
    Korean Journal of Radiology.2020; 21(7): 812.     CrossRef
  • 7,033 View
  • 183 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Youjin Kim, Tae Won Kim, Sae Won Han, Joong Bae Ahn, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat. 2019;51(3):1128-1134.   Published online November 21, 2018
DOI: https://doi.org/10.4143/crt.2018.379
AbstractAbstract PDFPubReaderePub
Purpose
Simvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, apoptosis, and anti-angiogenesis. This phase II trial evaluated the efficacy and toxicity profile of conventional XELOX and bevacizumab chemotherapy plus simvastatin in metastatic colorectal cancer patients (MCRC).
Materials and Methods
Patients with MCRC received first-line XELOX in 3-week treatment cycles of intravenous oxaliplatin 130 mg/m2 plus bevacizumab 7.5 mg/kg (day 1), followed by oral capecitabine 1,000 mg/m2 twice daily (day 1-14). Simvastatin 80 mg tablets were taken orally once daily every day during the period of chemotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, duration of response, overall survival (OS), time to progression, and toxicity.
Results
From January 2014 to April 2015, 60 patients were enrolled and 55 patients were evaluable for tumor response. The median follow-up duration was 30.1 months (range, 28.5 to 31.7 months). The median PFS was 10.4 months (95% confidence interval [CI], 9.6 to 11.1). The median OS of all patients was 19.0 months (95% CI, 11.9 to 26.0). The disease-control rate and overall response rate were 88.3% (95% CI, 74 to 96) and 58.3% (95% CI, 44 to 77), respectively, by intent-to-treat protocol analysis. There was one complete response and 34 partial responses. One patient experienced grade 3 creatine kinase elevation and liver enzyme elevation.
Conclusion
Based on the current study, the addition of 80 mg simvastatin to XELOX and bevacizumab showed comparable clinical efficacy in patients with MCRC as first-line chemotherapy and did not increase toxicity.

Citations

Citations to this article as recorded by  
  • Anticancer properties of histone deacetylase inhibitors – what is their potential?
    Kajetan Kiełbowski, Agata Szwedkowicz, Paulina Plewa, Estera Bakinowska, Rafał Becht, Andrzej Pawlik
    Expert Review of Anticancer Therapy.2025; : 1.     CrossRef
  • Therapeutic Effects of Statins: Promising Drug for Topical and Transdermal Administration
    Fatemeh Zahedipour, Seyede Atefe Hosseini, Željko Reiner, Eugenia Tedeschi-Reiner, Tannaz Jamialahmadi, Amirhossein Sahebkar
    Current Medicinal Chemistry.2024; 31(21): 3149.     CrossRef
  • Are statins onco- suppressive agents for every type of tumor? A systematic review of literature
    Luca Filaferro, Fabiana Zaccarelli, Giovanni Francesco Niccolini, Andrea Colizza, Federica Zoccali, Michele Grasso, Massimo Fusconi
    Expert Review of Anticancer Therapy.2024; 24(6): 435.     CrossRef
  • Cholesterol synthesis is essential for the growth of liver metastasis‐prone colorectal cancer cells
    Kumiko Taniguchi, Kei Sugihara, Takashi Miura, Daisuke Hoshi, Susumu Kohno, Chiaki Takahashi, Eishu Hirata, Etsuko Kiyokawa
    Cancer Science.2024; 115(11): 3817.     CrossRef
  • Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease
    Rong Jiang, Lian Lou, Wen Shi, Yuxiao Chen, Zhaoming Fu, Shuo Liu, Thida Sok, Zhihang Li, Xuan Zhang, Jian Yang
    International Journal of Molecular Sciences.2024; 25(18): 10177.     CrossRef
  • Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
    Claes R. Andersson, Jiawei Ye, Kristin Blom, Mårten Fryknäs, Rolf Larsson, Peter Nygren
    Anti-Cancer Drugs.2023; 34(1): 92.     CrossRef
  • A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors
    Thomas Cash, Hunter C. Jonus, Maya Tsvetkova, Jan H. Beumer, Arhanti Sadanand, Jasmine Y. Lee, Curtis J. Henry, Dolly Aguilera, R. Donald Harvey, Kelly C. Goldsmith
    Pediatric Blood & Cancer.2023;[Epub]     CrossRef
  • New insights into the therapeutic potentials of statins in cancer
    Chengyu Liu, Hong Chen, Bicheng Hu, Jiajian Shi, Yuchen Chen, Kun Huang
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • The Association of Metformin, Other Antidiabetic Medications, and Statins With the Prognosis of Colon Cancer in Patients With Type 2 Diabetes: A Retrospective Cohort Study
    Sami Erkinantti, Ari Hautakoski, Reijo Sund, Martti Arffman, Elina Urpilainen, Ulla Puistola, Arja Jukkola, Karihtala Peeter, Esa Läärä
    Cancer Control.2022;[Epub]     CrossRef
  • Performance of capecitabine in novel combination therapies in colorectal cancer
    Fahima Danesh Pouya, Yousef Rasmi, Irem Yalim Camci, Yusuf Tutar, Mohadeseh Nemati
    Journal of Chemotherapy.2021; 33(6): 375.     CrossRef
  • The potential use of simvastatin for cancer treatment: A review
    Jaqueline Aparecida Duarte, Andre Luis Branco de Barros, Elaine Amaral Leite
    Biomedicine & Pharmacotherapy.2021; 141: 111858.     CrossRef
  • Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis
    Navneet Kumar, Chandi C. Mandal
    Frontiers in Genetics.2021;[Epub]     CrossRef
  • Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
    Shangwei Zhong, Changhao Huang, Zhikang Chen, Zihua Chen, Jun-Li Luo
    Journal of Clinical Medicine.2021; 10(21): 5000.     CrossRef
  • Osteolytic metastasis in breast cancer: effective prevention strategies
    Chandi C Mandal
    Expert Review of Anticancer Therapy.2020; 20(9): 797.     CrossRef
  • 9,226 View
  • 222 Download
  • 18 Web of Science
  • 14 Crossref
Close layer
Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node–Positive Gastric Cancer Treated with Different Adjuvant Protocols
Jeong Il Yu, Do Hoon Lim, Jeeyun Lee, Won Ki Kang, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Seung Tae Kim, Su Jin Lee, Sung Kim, Tae Sung Sohn, Jun Ho Lee, Ji Yeong An, Min Gew Choi, Jae Moon Bae, Heejin Yoo, Kyunga Kim
Cancer Res Treat. 2019;51(3):876-885.   Published online October 1, 2018
DOI: https://doi.org/10.4143/crt.2018.401
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to compare prognostic differentiation performances of the 7th and the 8th edition of American Joint Commission on Cancer (AJCC) staging system for gastric cancer (GC) patients.
Materials and Methods
A total of 1,633 GC patients who underwent curative D2 resection followed by adjuvant chemotherapy alone (CA) or concurrent chemo-radiotherapy (CCRT) from 2004 to 2013 were included. Concordance index (c-index) was applied to compare the discriminatory ability.
Results
In the 8th edition, migration of stage was detected in 248 patients (15.2%). Among them, 121 patients were up-staged while 127 patients were down-staged. Overall, there was no statistically significant difference in the discriminatory ability between the 7th and 8th editions. The new edition of staging system, however, showed a trend of better prognostic performance not only in recurrence-free survival (c-index=0.734; 95% confidence interval [CI], 0.706 to 0.762 in the 7th edition vs. c-index=0.740; 95% CI, 0.712 to 0.768 in the 8th edition; p=0.14), but also in overall survival (c-index=0.717; 95% CI, 0.688 to 0.745 in the 7th edition vs. c-index=0.722; 95% CI, 0.694 to 0.751 in the 8th edition; p=0.19), especially in stage III. This finding was repeated in the subgroup analysis regardless of adjuvant CA or CCRT.
Conclusion
Generally, the 8th edition of AJCC staging system had failed to show a superior discriminatory ability for curatively D2 resected GC patients than the 7th edition, although there was a trend of better prognostic performance of the new edition, regardless of adjuvant treatment method.

Citations

Citations to this article as recorded by  
  • An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study
    Chao Cai, Cheng Chen, Xiuli Lin, Huihui Zhang, Mingming Shi, Xiaolei Chen, Weisheng Chen, Didi Chen
    Cancer Medicine.2024;[Epub]     CrossRef
  • Revolutionizing T3-4N0-2M0 gastric cancer staging with an innovative pathologic N classification system
    Kailai Yin, Xuanhong Jin, Yang Pan, Mengli Zi, Yingsong Zheng, Yubo Ma, Chuhong Pang, Kang liu, Jinxia Chen, Yizhou Wei, Dujiang Liu, Xiangdong Cheng, Li Yuan
    Journal of Gastrointestinal Surgery.2024; 28(8): 1283.     CrossRef
  • A Comprehensive Review of Prognostic Factors in Patients with Gastric Adenocarcinoma
    Styliani Mantziari, Penelope St Amour, Francesco Abboretti, Hugo Teixeira-Farinha, Sergio Gaspar Figueiredo, Caroline Gronnier, Dimitrios Schizas, Nicolas Demartines, Markus Schäfer
    Cancers.2023; 15(5): 1628.     CrossRef
  • Normalization weighted combination scores re-evaluate TNM staging of gastric cancer: a retrospective cohort study based on a multicenter database
    Junpeng Wu, Hao Wang, Xin Yin, Yufei Wang, Zhanfei Lu, Jiaqi Zhang, Yao Zhang, Yingwei Xue
    International Journal of Surgery.2023;[Epub]     CrossRef
  • A Substage Increase in The AJCC Classification System Improves Prognostic Prediction in Stage III Gastric Cancer With Insufficient Lymph Nodes Removed
    Ri-Sheng Zhao, Yi-Nan Liu, Wei-Gang Dai, Si-Le Chen, Jin-Ning Ye, Er-Tao Zhai, Shi-Rong Cai, Jian-Hui Chen
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer
    Jeong Il Yu, Hee Chul Park, Jeeyun Lee, Changhoon Choi, Won Ki Kang, Se Hoon Park, Seung Tae Kim, Tae Sung Sohn, Jun Ho Lee, Ji Yeong An, Min Gew Choi, Jae Moon Bae, Kyoung-Mee Kim, Heewon Han, Kyunga Kim, Sung Kim, Do Hoon Lim
    Cancers.2020; 12(4): 943.     CrossRef
  • 11,396 View
  • 228 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
Changhoon Yoo, Jihoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung-Ah Lee, Kyung-Hun Lee, Tae-You Kim, Baek-Yeol Ryoo
Cancer Res Treat. 2019;51(2):510-518.   Published online June 13, 2018
DOI: https://doi.org/10.4143/crt.2018.226
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The signal transducer and activator of transcription 3 (STAT3) signaling pathway might be a promising therapeutic target for hepatocellular carcinoma (HCC).
Materials and Methods
This study was a multicenter, open-label, non-comparative, dose escalating phase I study of OPB-111077, an oral STAT3 inhibitor, in patients with advanced HCC who failed on sorafenib. Continuous dosing (daily administration, 50 to 400 mg) and intermittent dosing (4-days on/3-days off administration: 300 to 900 mg) regimens were evaluated and the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended dose (RD) were the primary endpoints.
Results
A total of 33 patients (19 for continuous dosing and 14 for intermittent dosing) were enrolled. One patient experienced a DLT with grade 3 dizziness, but the MTD was identified in neither the continuous nor the intermittent dosing cohorts. The RDs were determined to be 250 mg for the continuous dosing regimen and 600 mg for the intermittent dosing regimen. There was no treatment-related death; five patients (15.2%) had grade 3-4 toxicities including thrombocytopenia (6%), fatigue (3%), and dizziness (3%). No patients achieved complete or partial responses and the median progression-free survival was 1.4 months (95% confidence interval, 0.8 to 2.8).
Conclusion
OPB-111077 was well tolerated in patients with advanced HCC after sorafenib failure, but only showed limited preliminary efficacy outcomes. Further investigation of the role of the STAT3 signaling pathway in HCC and the development of biomarkers for STAT3 inhibitors are warranted.

Citations

Citations to this article as recorded by  
  • Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer
    JunJun Jia, Xuelian Zhou, Qingfei Chu
    Molecular and Cellular Biochemistry.2025; 480(1): 1.     CrossRef
  • Structural Optimization and Characterization of Highly Potent and Selective STAT3 Inhibitors for the Treatment of Triple Negative Breast Cancer
    Wangrui Jin, Yuzhu Zhang, Baozhen Wang, Zhaoyong Kang, Huachao Li, Jingfeng Song, Yihua Chen, Hai Xiong, Jing Chen
    European Journal of Medicinal Chemistry.2025; : 117332.     CrossRef
  • Hepatocellular carcinoma: signaling pathways and therapeutic advances
    Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin
    Signal Transduction and Targeted Therapy.2025;[Epub]     CrossRef
  • Targeting JAK2/STAT3 for the treatment of cancer: A review on recent advancements in molecular development using structural analysis and SAR investigations
    Rupali Kohal, Priya Bisht, Ghanshyam Das Gupta, Sant Kumar Verma
    Bioorganic Chemistry.2024; 143: 107095.     CrossRef
  • Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
    Yamei Hu, Zigang Dong, Kangdong Liu
    Journal of Experimental & Clinical Cancer Research.2024;[Epub]     CrossRef
  • Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
    Greta Pessino, Claudia Scotti, Maristella Maggi
    Cancers.2024; 16(5): 901.     CrossRef
  • Isoalantolactone exerts anti‐melanoma effects via inhibiting PI3K/AKT/mTOR and STAT3 signaling in cell and mouse models
    Jun‐Kui Li, Xiao‐Li Jiang, Zhu Zhang, Wen‐Qing Chen, Jun‐Jie Peng, Bin Liu, Pei‐Li Zhu, Ken‐Kin‐Lam Yung
    Phytotherapy Research.2024; 38(6): 2800.     CrossRef
  • Prognostic and therapeutic potential of STAT3: Opportunities and challenges in targeting HPV-mediated cervical carcinogenesis
    Divya Janjua, Kulbhushan Thakur, Nikita Aggarwal, Apoorva Chaudhary, Joni Yadav, Arun Chhokar, Tanya Tripathi, Udit Joshi, Anna Senrung, Alok Chandra Bharti
    Critical Reviews in Oncology/Hematology.2024; 197: 104346.     CrossRef
  • Signaling pathways in liver cancer: pathogenesis and targeted therapy
    Yangtao Xue, Yeling Ruan, Yali Wang, Peng Xiao, Junjie Xu
    Molecular Biomedicine.2024;[Epub]     CrossRef
  • STAT3: Key targets of growth-promoting receptor positive breast cancer
    Rui-yuan Jiang, Jia-yu Zhu, Huan-ping Zhang, Yuan Yu, Zhi-xin Dong, Huan-huan Zhou, Xiaojia Wang
    Cancer Cell International.2024;[Epub]     CrossRef
  • Discovery, Optimization, and Evaluation of Novel N-(Benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine Analogues as Potent STAT3 Inhibitors for Cancer Treatment
    Ru Wang, Ting-Ting Du, Wen-Qiang Liu, Yi-Chen Liu, Ya-Dong Yang, Jin-Ping Hu, Ming Ji, Bei-Bei Yang, Li Li, Xiao-Guang Chen
    Journal of Medicinal Chemistry.2023; 66(17): 12373.     CrossRef
  • Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention
    Shuangfeng Li, Shuangshuang Yin, Hui Ding, Yingying Shao, Shiyue Zhou, Weiling Pu, Lifeng Han, Tao Wang, Haiyang Yu
    Cell Proliferation.2023;[Epub]     CrossRef
  • Eupalinolide J Inhibits Cancer Metastasis by Promoting STAT3 Ubiquitin-Dependent Degradation
    Hongtao Hu, Haoyang Bai, Lili Huang, Bo Yang, Huajun Zhao
    Molecules.2023; 28(7): 3143.     CrossRef
  • Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment
    Peng He, Aiwu Bian, Ying Miao, Wangrui Jin, Huang Chen, Jia He, Liting Li, Yue Sun, Jiangnan Ye, Mingyao Liu, Zhengfang Yi, Wenbo Zhou, Yihua Chen
    Journal of Medicinal Chemistry.2022; 65(22): 15487.     CrossRef
  • STAT3 pathway in cancers: Past, present, and future
    Han‐Qi Wang, Qi‐Wen Man, Fang‐Yi Huo, Xin Gao, Hao Lin, Su‐Ran Li, Jing Wang, Fu‐Chuan Su, Lulu Cai,, Yi Shi, Bing Liu,, Lin‐Lin Bu
    MedComm.2022;[Epub]     CrossRef
  • Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
    Yinjie Fan, Hang Xue, Huachuan Zheng
    Journal of Hepatocellular Carcinoma.2022; Volume 9: 233.     CrossRef
  • Constant Activation of STAT3 Contributes to the Development of Adenomyosis in Females
    Takehiro Hiraoka, Yasushi Hirota, Shizu Aikawa, Rei Iida, Chihiro Ishizawa, Tetsuaki Kaku, Tomoyuki Hirata, Yamato Fukui, Shun Akaeda, Mitsunori Matsuo, Ryoko Shimizu-Hirota, Norihiko Takeda, Yutaka Osuga
    Endocrinology.2022;[Epub]     CrossRef
  • Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
    Joaquín Martínez‑López, Pau Montesinos, Nieves López‑Muñoz, Rosa Ayala, Pilar Martínez‑Sánchez, Julian Gorrochategui, José Rojas‑Rudilla, Daniel Primo, Juan-Miguel Bergua‑Burgues, María Calbacho, Evelyn Acuña‑Cruz, José Pérez‑Simón, Adolfo De La Fuente, J
    Medicine International.2022;[Epub]     CrossRef
  • Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain
    Yaping Hua, Xing Yuan, Yun-heng Shen, Jinxin Wang, Waqas Azeem, Shuo Yang, Alexandra Gade, Seyed Mohammad Lellahi, Anne Margrete Øyan, Xisong Ke, Wei-dong Zhang, Karl-Henning Kalland
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment
    Peng He, Ying Miao, Yue Sun, Aiwu Bian, Wangrui Jin, Huang Chen, Jiangnan Ye, Jia He, Yangrui Peng, Haijun Gu, Mingyao Liu, Zhengfang Yi, Yihua Chen
    Journal of Medicinal Chemistry.2022; 65(19): 12650.     CrossRef
  • STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma
    Mingjing Jiang, Bo Li
    Cells.2022; 11(19): 3131.     CrossRef
  • NAFLD and HBV interplay - related mechanisms underlying liver disease progression
    Evanthia Tourkochristou, Stelios F. Assimakopoulos, Konstantinos Thomopoulos, Markos Marangos, Christos Triantos
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • An update on investigational therapies that target STAT3 for the treatment of cancer
    Matteo Santoni, Francesca Miccini, Alessia Cimadamore, Francesco Piva, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Nicola Battelli
    Expert Opinion on Investigational Drugs.2021; 30(3): 245.     CrossRef
  • Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors
    Dingding Gao, Nan Jin, Yixian Fu, Yueyue Zhu, Yujie Wang, Ting Wang, Yuehong Chen, Mingming Zhang, Qiang Xiao, Min Huang, Yingxia Li
    European Journal of Medicinal Chemistry.2021; 216: 113333.     CrossRef
  • NAFLD-Associated HCC: Progress and Opportunities
    Daniel Geh, Quentin M Anstee, Helen L Reeves
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 223.     CrossRef
  • The therapeutic potential of mitochondrial toxins
    Manabu Kawada, Masahide Amemiya, Junjiro Yoshida, Tomokazu Ohishi
    The Journal of Antibiotics.2021; 74(10): 696.     CrossRef
  • Advances of Targeted Therapy for Hepatocellular Carcinoma
    Mengke Niu, Ming Yi, Ning Li, Kongju Wu, Kongming Wu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma
    Shusil K. Pandit, Giada Sandrini, Jessica Merulla, Valentina Nobili, Xin Wang, Alessia Zangari, Andrea Rinaldi, Dheeraj Shinde, Giuseppina M. Carbone, Carlo V. Catapano
    Cancers.2021; 13(23): 6029.     CrossRef
  • Phosphotyrosine isosteres: past, present and future
    Robert A. Cerulli, Joshua A. Kritzer
    Organic & Biomolecular Chemistry.2020; 18(4): 583.     CrossRef
  • Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis
    Alessia Virzì, Armando Andres Roca Suarez, Thomas F. Baumert, Joachim Lupberger
    Cold Spring Harbor Perspectives in Medicine.2020; 10(1): a037366.     CrossRef
  • Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization
    Jan Jamroskovic, Mara Doimo, Karam Chand, Ikenna Obi, Rajendra Kumar, Kristoffer Brännström, Mattias Hedenström, Rabindra Nath Das, Almaz Akhunzianov, Marco Deiana, Kazutoshi Kasho, Sebastian Sulis Sato, Parham L. Pourbozorgi, James E. Mason, Paolo Medini
    Journal of the American Chemical Society.2020; 142(6): 2876.     CrossRef
  • JAK/STAT signaling in hepatocellular carcinoma
    Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh
    Hepatic Oncology.2020;[Epub]     CrossRef
  • Targeting apoptosis in cancer therapy
    Benedito A. Carneiro, Wafik S. El-Deiry
    Nature Reviews Clinical Oncology.2020; 17(7): 395.     CrossRef
  • Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions
    Yuxin Tan, Qiuji Wu, Fuling Zhou
    Critical Reviews in Oncology/Hematology.2020; 152: 102993.     CrossRef
  • Manipulation of JAK/STAT Signalling by High-Risk HPVs: Potential Therapeutic Targets for HPV-Associated Malignancies
    Ethan L. Morgan, Andrew Macdonald
    Viruses.2020; 12(9): 977.     CrossRef
  • STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation
    Périne Millot, Carine San, Evangeline Bennana, Baptiste Porte, Nicolas Vignal, Jacques Hugon, Claire Paquet, Benoit Hosten, François Mouton-Liger
    Immunology Letters.2020; 228: 129.     CrossRef
  • STAT3 Inhibitor OPB-51602 Is Cytotoxic to Tumor Cells Through Inhibition of Complex I and ROS Induction
    Lara Brambilla, Tanaya Lahiri, Michael Cammer, David E. Levy
    iScience.2020; 23(12): 101822.     CrossRef
  • Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes
    Chen-Hao Zhang, Ming Li, You-Pei Lin, Qiang Gao
    Current Gene Therapy.2020; 20(2): 84.     CrossRef
  • STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
    Jiang-Jiang Qin, Li Yan, Jia Zhang, Wei-Dong Zhang
    Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
  • Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma
    Kazuki Takakura, Tsunekazu Oikawa, Masanori Nakano, Chisato Saeki, Yuichi Torisu, Mikio Kajihara, Masayuki Saruta
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Direct Targeting Options for STAT3 and STAT5 in Cancer
    Anna Orlova, Christina Wagner, Elvin D. de Araujo, Dávid Bajusz, Heidi A. Neubauer, Marco Herling, Patrick T. Gunning, György M. Keserű, Richard Moriggl
    Cancers.2019; 11(12): 1930.     CrossRef
  • 10,467 View
  • 309 Download
  • 40 Web of Science
  • 41 Crossref
Close layer
Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
Ki Sun Jung, Su Jin Lee, Se Hoon Park, Jae-Lyun Lee, Se-Hoon Lee, Jae Yun Lim, Jung Hun Kang, Suee Lee, Sun Young Rha, Kyung Hee Lee, Ho Young Kim, Ho Yeong Lim
Cancer Res Treat. 2018;50(2):488-494.   Published online May 22, 2017
DOI: https://doi.org/10.4143/crt.2016.584
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC.
Materials and Methods
Patientswith locally advanced or metastatic nccRCC, exceptfor collecting duct or sarcomatoid type, received 800 mg/day of pazopanib daily until progression of disease or intolerable toxicity. One cyclewas defined as 4weeks and tumorresponsewas evaluated every two cycles. The primary objective was overall response rate (ORR).
Results
A total of 29 eligible patients were enrolled at nine centers in Korea from December 2012 and September 2014. The median age of the patients was 58 years (range, 27 to 76 years) and 21 patients (72%) were male. Regarding histology type, 19 patients had papillary, three had chromophobe, two had unclassified and five had unknown non-clear cell type. Of 28 evaluable patients, eight achieved a confirmed partial response with ORR of 28%. The median progression-free survival was 16.5 months (95% confidence interval, 10.9 to 22.1) and median overall survival was not reached. Sixteen patients (55%) experienced treatment-related toxicity of grade 3 or more, but most adverse events were overcome through dose reduction and delay.
Conclusion
In this prospective phase II study, pazopanib demonstrated promising activity and tolerable safety profile in patients with metastatic nccRCC.

Citations

Citations to this article as recorded by  
  • Systemic therapy for non–clear cell renal cell carcinomas: A systematic review
    Balqees Ara, Anum Babar, Durkho Atif, Bushra Ghafoor, Mustafa Shah, Syed Maaz Abdullah, Danish Safi, Amir Kamran
    Journal of Oncology Pharmacy Practice.2025; 31(1): 128.     CrossRef
  • Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
    Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
    International Journal of Cancer.2024; 154(6): 947.     CrossRef
  • Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
    Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves e Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P. Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andra
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Papillary Renal Cell Carcinoma: Current Evidence and Future Directions
    Albert Jang, Charbel S. Hobeika, Shilpa Gupta
    Kidney Cancer.2024; 8(1): 61.     CrossRef
  • Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
    Hasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, Nargız Majidova, Tugay Avci, Halil Göksel Güzel, Caner Kapar, Mehmet Uzun, Perihan Perkin, Fahri Akgül, Saadet Sim Yildirim, Seda Sali, Anil Yildiz, Seher Nazli Kazaz, Engin Hendem, Murat Arcagok, G
    Journal of Chemotherapy.2024; : 1.     CrossRef
  • Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective
    Gaetano Pezzicoli, Vittoria Musci, Federica Ciciriello, Francesco Salonne, Paola Cafforio, Nicoletta Lionetti, Anna Ragno, Mimma Rizzo
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis
    Yaping Zhang, Jian Chen, Xiaoyan Wang, Hui Wang, Xiaoli Chen, Jianfeng Hong, Hongming Fang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma
    Floriane Izarn, Benoît Allignet, Romane Gille, Helen Boyle, Eve-Marie Neidhardt, Sylvie Négrier, Aude Fléchon
    Clinical Genitourinary Cancer.2023; 21(2): e35.     CrossRef
  • SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
    María José Méndez-Vidal, Martin Lázaro Quintela, Nuria Lainez-Milagro, Begoña Perez-Valderrama, Cristina Suárez Rodriguez, José Ángel Arranz Arija, Ignacio Peláez Fernández, Enrique Gallardo Díaz, Julio Lambea Sorrosal, Aránzazu González-del-Alba
    Clinical and Translational Oncology.2023; 25(9): 2732.     CrossRef
  • Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium
    Cihan Erol, Emre Yekedüz, Deniz Tural, Serdar Karakaya, Nihan Şentürk Öztaş, Gökhan Uçar, Saadettin Kılıçkap, İsmail Ertürk, Özlem Nuray Sever, Çağatay Arslan, Ahmet Küçükarda, Orçun Can, Özlem Balvan, Satı Coşkun Yazgan, Mustafa Özgüroğlu, Berna Öksüzoğl
    Urologia Internationalis.2023; 107(6): 595.     CrossRef
  • The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non‐clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database
    Tomoyuki Koguchi, Sei Naito, Shingo Hatakeyama, Kazuyuki Numakura, Yumina Muto, Renpei Kato, Takahiro Kojima, Yoshihide Kawasaki, Kento Morozumi, Shuya Kandori, Sadafumi Kawamura, Hiroyuki Nishiyama, Akihiro Ito, Tomonori Habuchi, Wataru Obara, Chikara Oh
    Cancer Medicine.2023; 12(22): 20677.     CrossRef
  • Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
    Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Pay
    Journal of the National Comprehensive Cancer Network.2022; 20(1): 71.     CrossRef
  • Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma
    Jason R. Brown, Adam Calaway, Erik Castle, Jorge Garcia, Pedro C. Barata
    Kidney Cancer.2022; 6(1): 53.     CrossRef
  • Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches
    Niloofar Khoshdel Rad, Maryam Vahidyeganeh, Mahsa Mohammadi, Anastasia Shpichka, Peter Timashev, Nikoo Hossein-Khannazer, Massoud Vosough
    International Journal of Translational Medicine.2022; 2(4): 555.     CrossRef
  • Systemic Therapies for the Management of Non–Clear Cell Renal Cell Carcinoma: What Works, What Doesn’t, and What the Future Holds
    Panagiotis Zoumpourlis, Giannicola Genovese, Nizar M. Tannir, Pavlos Msaouel
    Clinical Genitourinary Cancer.2021; 19(2): 103.     CrossRef
  • Comprehensive review of chromophobe renal cell carcinoma
    Rohan Garje, Dean Elhag, Hesham A Yasin, Luna Acharya, Daniel Vaena, Laila Dahmoush
    Critical Reviews in Oncology/Hematology.2021; 160: 103287.     CrossRef
  • A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma
    Chelsea K. Osterman, Tracy L. Rose
    Kidney Cancer.2020; 4(1): 15.     CrossRef
  • Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report
    Ivana Puliafito, Alessio Russo, Dorotea Sciacca, Caterina Puglisi, Dario Giuffrida
    Journal of Medical Case Reports.2020;[Epub]     CrossRef
  • On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
    Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier
    American Society of Clinical Oncology Educational Book.2020; (40): 418.     CrossRef
  • Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
    Melissa Bersanelli, Matteo Brunelli, Letizia Gnetti, Umberto Maestroni, Sebastiano Buti
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • Management of Metastatic Renal Cell Carcinoma with Variant Histologies
    Ronan Flippot, Vijay Damarla, Bradley A. McGregor
    Urologic Clinics of North America.2020; 47(3): 319.     CrossRef
  • Discovery of Pyrido[3′,2′:5,6]thiopyrano[4,3-d]pyrimidine-Based Antiproliferative Multikinase Inhibitors
    Silvia Salerno, Elisabetta Barresi, Aída Nelly García-Argáez, Sabrina Taliani, Francesca Simorini, Giorgio Amendola, Stefano Tomassi, Sandro Cosconati, Ettore Novellino, Federico Da Settimo, Anna Maria Marini, Lisa Dalla Via
    ACS Medicinal Chemistry Letters.2019; 10(4): 457.     CrossRef
  • Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
    Nieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, Hannah Dzimitrowicz, Jarred Burkart, Daniel M Geynisman, Archana Balakrishnan, I Alex Bowman, Rohit Jain, Walter Stadler, Yousef Zakharia, Vivek Narayan, Benoit Beuselinck, Rana R McKay, Abhishek Tri
    The Lancet Oncology.2019; 20(4): 581.     CrossRef
  • Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas
    Keiichi Ito
    International Journal of Urology.2019; 26(9): 868.     CrossRef
  • Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
    Inkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong, Jae Lyun Lee
    BMC Urology.2019;[Epub]     CrossRef
  • Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
    Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
    Cancer Research and Treatment.2019; 51(4): 1578.     CrossRef
  • The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review
    Gregory T. Sneed, Sukdong Lee, Jamie N. Brown, Julia M. Hammond
    Clinical Genitourinary Cancer.2019; 17(6): 419.     CrossRef
  • A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non–clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus
    Inkeun Park, Se Hoon Lee, Jae Lyun Lee
    Clinical Genitourinary Cancer.2018; 16(5): e997.     CrossRef
  • Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan
    Keiichi Ito, Shuji Mikami, Katsunori Tatsugami, Naoya Masumori, Nobuo Shinohara, Tsunenori Kondo, Shotaro Nakanishi, Yoji Nagashima, Masatoshi Eto, Tomomi Kamba, Naoto Kuroda, Yoshihiko Tomita, Hideyasu Matsuyama, Tetsuro Onishi, Tomoyasu Tsushima, Hayaka
    Clinical Genitourinary Cancer.2018; 16(6): e1201.     CrossRef
  • 10,742 View
  • 491 Download
  • 37 Web of Science
  • 29 Crossref
Close layer
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
Yunjung Choi, Mi Sun Yun, Sang Hee Lim, Jeeyun Lee, Jin-Hee Ahn, Yu Jung Kim, Kyong Hwa Park, Young Suk Park, Ho Yeong Lim, Hyonggin An, Dong-Churl Suh, Yeul Hong Kim
Cancer Res Treat. 2018;50(1):175-182.   Published online March 30, 2017
DOI: https://doi.org/10.4143/crt.2016.535
AbstractAbstract PDFPubReaderePub
Purpose
This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence.
Materials and Methods
A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients.
Results
A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1% (34/218, in the leiomyosarcoma subgroup; 26.3%). The median overall survival and progression-free survival were 10.3 months (95% confidence interval [CI], 8.4 to 12.2) and 3.3 months (95% CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8% of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7%) and anemia (15.1%) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged ≤ 50 years had a hazard ratio of 1.388 (95% CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95% CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes.
Conclusion
GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option.

Citations

Citations to this article as recorded by  
  • Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma
    Shuang Liang, Lanting Ji, Zhenyuan Yu, YaHsin Cheng, Ruifang Gao, Wenpeng Yan, Fang Zhang
    Hereditas.2024;[Epub]     CrossRef
  • Comparative Evaluation of Second-Line Chemotherapy Agents for Advanced Soft Tissue Sarcoma: Gemcitabine/Docetaxel, Pazopanib, and Alternatives
    Tae Hun Kim, Ki Hyuk Sung, So Hak Chung
    Journal of the Korean Orthopaedic Association.2024; 59(1): 22.     CrossRef
  • Leiomyosarcoma of stomach extending to gastroesophageal junction and distal esophagus as a rare cause of dysphagia -A case report
    Lilamani Rajthala, Sagar Gyawali, Sabin Banmala, Surendra Shah
    Annals of Medicine & Surgery.2024;[Epub]     CrossRef
  • Real‐World Outcomes of Patients Treated With Gemcitabine Using Standardized Dose and Rate and Docetaxel for Advanced Soft Tissue Sarcoma in an Australian Sarcoma Center
    Isabella Wilson, Madeleine Strach, Vivek Bhadri, Michelle Harrison, Whiter Tang, Peter Grimison
    Asia-Pacific Journal of Clinical Oncology.2024;[Epub]     CrossRef
  • Retrospective evaluation of the role of gemcitabine‐docetaxel in well‐differentiated and dedifferentiated liposarcoma
    Prapassorn Thirasastr, Heather Lin, Behrang Amini, Wei‐Lien Wang, Jeffrey M. Cloutier, Elise F. Nassif, Emily Z. Keung, Christina L. Roland, Barry Feig, Dejka Araujo, Robert S. Benjamin, Anthony P. Conley, John A. Livingston, Joseph Ludwig, Shreyaskumar P
    Cancer Medicine.2023; 12(4): 4282.     CrossRef
  • Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
    Tuyen Duong Thanh Nguyen, Yan Wang, Tuyen N. Bui, Rossana Lazcano, Davis R. Ingram, Min Yi, Varshini Vakulabharanam, Linjie Luo, Marc A. Pina, Cansu Karakas, Mi Li, Nicole M. Kettner, Neeta Somaiah, Peter J. Hougton, Osama Mawlawi, Alexander J. Lazar, Kel
    Cancer Research.2023; 83(6): 939.     CrossRef
  • A competing risk-based nomogram to predict cancer-specific survival in patients with retroperitoneal leiomyosarcoma
    Qian Fang, Guojing Cai, Guizeng Chen, Xiang Xu, Haifeng Zeng, Yulong He, Shirong Cai, Hui Wu
    Heliyon.2023; 9(6): e16867.     CrossRef
  • Chemotherapeutic drugs for soft tissue sarcomas: a review
    Zhichao Tian, Weitao Yao
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcoma
    Szu-Yun Niu, Lou Sun, Shih-Tien Hsu, Sheau-Feng Hwang, Chih-Ku Liu, Yu-Hsiang Shih, Ting-Fang Lu, Yen-Fu Chen, Li-Ching Lai, Pei-Lun Chang, Chien-Hsing Lu
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center’s experience and review of literature
    Siran Yang, Wenqing Wang, Nan Bi, Zongmei Zhou, Qinfu Feng, Zefen Xiao, Dongfu Chen, Jun Liang, Jima Lu, Jianyang Wang, Xin Wang, Jingbo Wang, Yong Yang, Ningning Lu, Hongxing Zhang, Luhua Wang
    Medicine.2022; 101(42): e31215.     CrossRef
  • Synovial sarcoma in children: A 15-YEAR experience at a tertiary pediatric center in Argentina
    E. Rossetti, G. Gonzalez Diaz, J. Lopez Marti, S. Innocenti, W. Cacciavillano, G. Felizzia, M. Viso, M.L. Ramos, P. Zubizarreta, A. Rose
    Pediatric Hematology Oncology Journal.2021; 6(4): 175.     CrossRef
  • Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas
    Dennis Christoph Harrer, Sebastian Buschauer, Ulrich Sterz, Karin Menhart, Christina Wendl, Daniel Heudobler, Matthias Grube, Tobias Pukrop, Wolfgang Herr, Martin Vogelhuber
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Gemcitabine induced cytotoxicity, DNA damage and hepatic injury in laboratory mice
    Waleed A. Q. Hailan, Faisal M. Abou-Tarboush, Khalid M. Al-Anazi, Areeba Ahmad, Ahmed Qasem, Mohammad Abul Farah
    Drug and Chemical Toxicology.2020; 43(2): 158.     CrossRef
  • Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma
    Eun Byeol Jo, Doopyo Hong, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Sung Joo Kim
    Translational Oncology.2019; 12(2): 269.     CrossRef
  • Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
    Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi
    Laboratory Investigation.2019; 99(9): 1309.     CrossRef
  • The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model
    Kentaro Miyake, Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Norihiko Sugisawa, Jun Ho Park, Sahar Razmjooei, Yuki Katsuya, Maryam Barangi, Yunfeng Li, Scott D. Nelson, Takashi Murakami, Yuki Homma, Yukihiko Hiroshima, Ryusei Matsuyama, Michael Bouve
    Biomedicine & Pharmacotherapy.2019; 117: 109093.     CrossRef
  • Adipogenesis induces growth inhibition of dedifferentiated liposarcoma
    Yu Jin Kim, Dan Bi Yu, Mingi Kim, Yoon‐La Choi
    Cancer Science.2019; 110(8): 2676.     CrossRef
  • Leiomyosarcoma of the Stomach with Metastasis to the Liver: A Case Report With Review of the Literature
    Varshil Mehta, Monali Rajawat, Sameer Rastogi, Ravi H Phulware, Roman Mezencev
    Future Science OA.2018;[Epub]     CrossRef
  • Systemic treatment in adult uterine sarcomas
    I.M.E. Desar, P.B. Ottevanger, C. Benson, W.T.A. van der Graaf
    Critical Reviews in Oncology/Hematology.2018; 122: 10.     CrossRef
  • Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature
    Tomoko Yoshimoto, Shinichiro Kobayashi, Kengo Kanetaka, Kazuma Kobayashi, Yasuhiro Nagata, Michi Morita, Yuriko Isagawa, Naoe Kinoshita, Mitsuhisa Takatsuki, Susumu Eguchi
    Surgical Case Reports.2018;[Epub]     CrossRef
  • 13,124 View
  • 365 Download
  • 18 Web of Science
  • 20 Crossref
Close layer
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
Do Young Kim, Hye Jin Kim, Kwang-Hyub Han, Sang Young Han, Jeong Heo, Hyun Young Woo, Soon Ho Um, Yeul Hong Kim, Young Oh Kweon, Ho Yeong Lim, Jung Hwan Yoon, Wan Sik Lee, Byung Seok Lee, Han Chu Lee, Baek-Yeol Ryoo, Seung Kew Yoon
Cancer Res Treat. 2016;48(4):1243-1252.   Published online February 24, 2016
DOI: https://doi.org/10.4143/crt.2015.278
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study).
Materials and Methods
Between January 2009 and April 2012, a total of 497 patients were enrolled from 11 sites in Korea. Of these, 482 patients were evaluable for safety analyses. Case report forms of paper or electronic version were used to record safety and efficacy data from all patients.
Results
More patients of Child-Pugh A received sorafenib for > 8 weeks than did patients of Child-Pugh B (55.5% vs. 34.3%). Child-Pugh score did not appear to influence the starting dose of sorafenib, and approximately 70% of patients both in Child-Pugh A and B groups received the recommended initial daily dose of 800 mg (69.0% and 69.5%, respectively). The median overall survival (OS) and time to progression (TTP) were 8.5 months and 2.5 months. In Child-Pugh A patients, the median OS and TTP were 10.2 months and 2.5 months. The most frequent treatment-emergent drug-related adverse event was hand-foot skin reaction (31.7%), followed by diarrhea (18.0%). The incidence of treatment-emergent adverse events was similar in both Child-Pugh A (85.4%) and Child-Pugh B (84.8%) patients.
Conclusion
Sorafenib was well tolerated by Korean HCC patients in clinical settings, and the safety profile did not appear to differ by Child-Pugh status. Survival benefit in Korean patients was in line with that of a previous pivotal phase III trial (SHARP).

Citations

Citations to this article as recorded by  
  • Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea
    Sojung Han, Do Young Kim, Ho Yeong Lim, Jung-Hwan Yoon, Baek-Yeol Ryoo, Yujeong Kim, Kookhee Kim, Bo Yeon Kim, So Young Yi, Dong-Sook Kim, Do-Yeon Cho, Jina Yu, Suhyun Kim, Joong-Won Park
    Gut and Liver.2024; 18(1): 116.     CrossRef
  • Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor
    Po-Ting Lin
    American Journal of Cancer Research.2024; 14(3): 1306.     CrossRef
  • Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review
    Florian P. Reiter, Najib Ben Khaled, Liangtao Ye, Changhua Zhang, Max Seidensticker, Mark op den Winkel, Gerald Denk, Andreas Geier, Enrico N. De Toni
    Digestive Diseases.2022; 40(5): 565.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research
    Francesca Negri, Gabriele Missale, Anna Degli Antoni, Camillo Porta
    Translational Oncology.2021; 14(9): 101153.     CrossRef
  • Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial
    Beom Kyung Kim, Do Young Kim, Hwa Kyung Byun, Hye Jin Choi, Seung-Hoon Beom, Hye Won Lee, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jinsil Seong, Kwang-Hyub Han
    International Journal of Radiation Oncology*Biology*Physics.2020; 107(1): 106.     CrossRef
  • Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin
    Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Jong Yul Lee, Young Woon Kim, Dong Jae Shim, Sung Won Lee, Jeong Won Jang
    Cancer Control.2020;[Epub]     CrossRef
  • Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry
    Young Eun Chon, Han Ah Lee, Jun Sik Yoon, Jun Yong Park, Bo Hyun Kim, In Joon Lee, Suk Kyun Hong, Dong Hyeon Lee, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee
    Journal of Liver Cancer.2020; 20(2): 135.     CrossRef
  • Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion


    Sojung Han, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Dai Hoon Han, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 403.     CrossRef
  • Sorafenib: key lessons from over 10 years of experience
    Bernard Escudier, Francis Worden, Masatoshi Kudo
    Expert Review of Anticancer Therapy.2019; 19(2): 177.     CrossRef
  • Liver Transplantation after Successful Downstaging with Hepatic Arterial Infusion Chemotherapy in a Patient with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
    Hee Chul Nam, Pil Soo Sung, Ho Jong Chun, Dong Goo Kim, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
    Journal of Liver Cancer.2019; 19(1): 64.     CrossRef
  • 18F–fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment
    Pil Soo Sung, Hye Lim Park, Keungmo Yang, Seawon Hwang, Myeong Jun Song, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Ie Ryung Yoo, Si Hyun Bae
    European Journal of Nuclear Medicine and Molecular Imaging.2018; 45(3): 384.     CrossRef
  • Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial
    Nikhil Chauhan, Janet Bukovcan, Eveline Boucher, David Cosgrove, Julien Edeline, Bonnie Hamilton, Laura Kulik, Fayaz Master, Riad Salem
    JMIR Research Protocols.2018; 7(8): e11234.     CrossRef
  • Sorafenib: A Review in Hepatocellular Carcinoma
    Gillian M. Keating
    Targeted Oncology.2017; 12(2): 243.     CrossRef
  • Treatment options after sorafenib failure in patients with hepatocellular carcinoma
    Imane El Dika, Ghassan K. Abou-Alfa
    Clinical and Molecular Hepatology.2017; 23(4): 273.     CrossRef
  • Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway
    Sung Hoon Choi, Hyemi Kim, Hyun Gyu Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    Oncotarget.2017; 8(35): 58974.     CrossRef
  • 13,964 View
  • 308 Download
  • 22 Web of Science
  • 16 Crossref
Close layer
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
Jun Ho Yi, Jung Hun Kang, In Gyu Hwang, Hee Kyung Ahn, Hyun Jin Baek, Soon Il Lee, Do Hyoung Lim, Young-Woong Won, Jun Ho Ji, Hyo Song Kim, Sun Young Rha, Sung Yong Oh, Kyung Eun Lee, Taekyu Lim, Chi Hoon Maeng, Moon Jin Kim, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Se Hoon Park
Cancer Res Treat. 2016;48(2):553-560.   Published online August 10, 2015
DOI: https://doi.org/10.4143/crt.2015.155
AbstractAbstract PDFPubReaderePub
Purpose
While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy.
Materials and Methods
Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively.
Results
A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025).
Conclusion
While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.

Citations

Citations to this article as recorded by  
  • Timing to Surgery and Lymph Node Upstaging in Gastric Cancer: An NCDB Analysis
    Maria Cristina Riascos, Jacques A. Greenberg, Federico Palacardo, Rodrigo Edelmuth, V. Colby Lewis, Anjile An, Haythem Najah, Hala Al Asadi, Parima Safe, Brendan M. Finnerty, Paul J. Christos, Thomas J. Fahey, Rasa Zarnegar
    Annals of Surgical Oncology.2024; 31(3): 1714.     CrossRef
  • Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study
    Katharina Kolbe, Ivonne Haffner, Katrin Schierle, Dieter Maier, Birgitta Geier, Birgit Luber, Hendrik Bläker, Christian Wittekind, Florian Lordick
    Journal of Cancer Research and Clinical Oncology.2023; 149(3): 1319.     CrossRef
  • Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer
    Chang Gon Kim, Minkyu Jung, Hyo Song Kim, Choong-kun Lee, Hei-Cheul Jeung, Dong-Hoe Koo, Woo Kyun Bae, Dae Young Zang, Bum Jun Kim, Hyunki Kim, Un-Jung Yun, Jingmin Che, Sejung Park, Tae Soo Kim, Woo Sun Kwon, Juin Park, Sang Woo Cho, Chung Mo Nam, Hyun C
    Journal of Clinical Oncology.2023; 41(27): 4394.     CrossRef
  • Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Juin Park, Sun Kyoung Kang, Woo Sun Kwon, Inhye Jeong, Tae Soo Kim, Seo Young Yu, Sang Woo Cho, Hyun Cheol Chung, Sun Young Rha
    Scientific Reports.2023;[Epub]     CrossRef
  • Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysis
    Wan-Ying Lin, Shih-Syuan Wang, Yi-No Kang, Andrea S. Porpiglia, Yu Chang, Chin-Hsuan Huang, Ronak Bhimani, Eahab Abdul-Lattif, Muneeba Azmat, Tsu-Hsien Wang, Yu-Shiuan Lin, Yu-Cheng Chang, Kuan-Yu Chi
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer
    S.J. Merchant, W. Kong, B. Gyawali, T. Hanna, W. Chung, S. Nanji, S.V. Patel, C.M. Booth
    Clinical Oncology.2021; 33(3): 202.     CrossRef
  • Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
    Tae-Hwan Kim, Hun Do Cho, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
    BMC Cancer.2021;[Epub]     CrossRef
  • HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study
    Ivonne Haffner, Katrin Schierle, Elba Raimúndez, Birgitta Geier, Dieter Maier, Jan Hasenauer, Birgit Luber, Axel Walch, Katharina Kolbe, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Beate Rau, Ludwig Fischer von Weikersthal, Miriam Ahlborn, Gabriele S
    Journal of Clinical Oncology.2021; 39(13): 1468.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer
    Atakan Topcu, Muhammed Mustafa Atci, Saban Secmeler, Mehmet Besiroglu, Murat Ayhan, Metin Ozkan, Oktay Bozkurt, Zuhat Urakci, Seval Ay, Caglayan Geredeli, Ayse Irem Yasin, Haci Mehmet Turk
    Future Oncology.2021; 17(31): 4157.     CrossRef
  • Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States


    Lisa M Hess, Michael Grabner, Liya Wang, Astra M Liepa, Xiaohong Ivy Li, Zhanglin Lin Cui, Lee Bowman, William R Schelman
    Pragmatic and Observational Research.2020; Volume 11: 27.     CrossRef
  • Targeting HER2-positive gastric cancer with a novel 18F-labeled ZHER2:342 probe
    Yunyun Pan, Zhengyang Yang, Yuping Xu, Zhicheng Bai, Donghui Pan, Runlin Yang, Lizhen Wang, Wenxian Guan, Min Yang
    RSC Advances.2019; 9(19): 10990.     CrossRef
  • Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients
    Sumi Yun, Jiwon Koh, Soo Kyung Nam, Jung Ok Park, Sung Mi Lee, Kyoungyul Lee, Kyu Sang Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Gheeyoung Choe, Woo Ho Kim, Hye Seung Lee
    Gastric Cancer.2018; 21(2): 225.     CrossRef
  • Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis
    A. Ilhan-Mutlu, H. Taghizadeh, A. Beer, W. Dolak, A. Ba-Ssalamah, S. F. Schoppmann, M. Hejna, P. Birner, M. Preusser
    Cancer Biology & Therapy.2018; 19(3): 169.     CrossRef
  • Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer
    Giandomenico Roviello, Roberto Petrioli, Valerio Nardone, Pietro Rosellini, Andrea Giovanni Multari, Raffaele Conca, Michele Aieta
    Medicine.2018; 97(20): e10745.     CrossRef
  • 14,449 View
  • 167 Download
  • 18 Web of Science
  • 15 Crossref
Close layer
Review Article
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
Joon Oh Park, Do-Youn Oh, Chiun Hsu, Jen-Shi Chen, Li-Tzong Chen, Mauro Orlando, Jong Seok Kim, Ho Yeong Lim
Cancer Res Treat. 2015;47(3):343-361.   Published online May 18, 2015
DOI: https://doi.org/10.4143/crt.2014.308
AbstractAbstract PDFPubReaderePub
Evidence suggests that combined gemcitabine-cisplatin chemotherapy extends survival in patients with advanced biliary tract cancer (BTC). We conducted a systematic review in order to collate this evidence and assess whether gemcitabine-cisplatin efficacy is influenced by primary tumor site, disease stage, or geographic region, and whether associated toxicities are related to regimen. MEDLINE (1946-search date), EMBASE (1966-search date), ClinicalTrials. gov (2008-search date), and abstracts from major oncology conferences (2009- search date) were searched (5 Dec 2013) using terms for BTC, gemcitabine, and cisplatin. All study types reporting efficacy (survival, response rates) or safety (toxicities) outcomes of gemcitabine-cisplatin in BTC were eligible for inclusion; efficacy data were extracted from prospective studies only. Evidence retrieved from one meta-analysis (abstract), four randomized controlled trials, 12 nonrandomized prospective studies, and three retrospective studies supported the efficacy and safety of gemcitabine-cisplatin for BTC. Median overall survival ranged from 4.6 to 11.7 months, and response rate ranged from 17.1% to 36.6%. Toxicities were generally acceptable and manageable. Heterogeneity in study designs and data collected prevented formal meta-analysis, however exploratory assessments suggested that efficacy did not vary with primary tumor site (gallbladder vs. others), disease stage (metastatic vs. locally advanced), or geographic origin (Asia vs. other). Incidence of grade 3/4 toxicities was not related to gemcitabine dose or cisplatin frequency. Despite individual variation in study designs, the evidence presented suggests that gemcitabine-cisplatin is effective in patients from a diverse range of countries and with heterogeneous disease characteristics. No substantial differences in toxicity were observed among the different dosing schedules of gemcitabine and cisplatin.

Citations

Citations to this article as recorded by  
  • S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion
    Sabrina Groß, Michael Bitzer, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(01): 73.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
    Michael Bitzer, Sabrina Groß, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(01): e67.     CrossRef
  • Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone
    Masaaki Kagoura, Shin Kobayashi, Motohiro Kojima, Masashi Kudo, Motokazu Sugimoto, Masaru Konishi, Naoto Gotohda
    European Journal of Surgical Oncology.2024; 50(3): 107980.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0
    Sabrina Groß, Michael Bitzer, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(02): e213.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion
    Michael Bitzer, Sabrina Groß, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(02): 231.     CrossRef
  • Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
    Howard A Burris, Takuji Okusaka, Arndt Vogel, Myung Ah Lee, Hidenori Takahashi, Valeriy Breder, Jean-Frédéric Blanc, Junhe Li, Melinda Bachini, Magdalena Żotkiewicz, Jayne Abraham, Nikunj Patel, Julie Wang, Muzammil Ali, Nana Rokutanda, Gordon Cohen, Do-Y
    The Lancet Oncology.2024; 25(5): 626.     CrossRef
  • Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models
    Niranjan Awasthi, Lily Darman, Margaret A. Schwarz, Roderich E. Schwarz
    Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
  • Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
    Tian-mei Zeng, Guang Yang, Cheng Lou, Wei Wei, Chen-jie Tao, Xi-yun Chen, Qin Han, Zhuo Cheng, Pei-pei Shang, Yu-long Dong, He-ming Xu, Lie-ping Guo, Dong-sheng Chen, Yun-jie Song, Chuang Qi, Wang-long Deng, Zhen-gang Yuan
    Nature Communications.2023;[Epub]     CrossRef
  • S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
    Michael Bitzer, Sabrina Groß, Jörg Albert, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Andreas Geier, Eleni Gkika, Martin Götz, Thomas Helmberger, Ralf-Thorsten Hoffmann, Peter Huppert, Achim Kau
    Zeitschrift für Gastroenterologie.2023; 61(04): e92.     CrossRef
  • S3-Leitlinie Diagnostik und Therapie biliärer Karzinome
    Michael Bitzer, Sabrina Groß, Jörg Albert, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Andreas Geier, Eleni Gkika, Martin Götz, Thomas Helmberger, Ralf-Thorsten Hoffmann, Peter Huppert, Achim Kau
    Zeitschrift für Gastroenterologie.2023; 61(04): 420.     CrossRef
  • Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
    Susanna Slater, David Cunningham
    The Lancet.2023; 401(10391): 1826.     CrossRef
  • Anti-Cancer Activity of Verteporfin in Cholangiocarcinoma
    Jihye L. Golino, Xin Wang, Jing Bian, Benjamin Ruf, Michael Kelly, Baktiar O. Karim, Maggie C. Cam, Changqing Xie
    Cancers.2023; 15(9): 2454.     CrossRef
  • Very rare metastatic phenomena of biliary tract cancer to the cerebellum: A case report and review of the literature
    Oadi N. Shrateh, Shadi Abu Saa
    International Journal of Surgery Case Reports.2023; 111: 108819.     CrossRef
  • Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population
    Tiantian Wu, Changsheng Pu, Qiang Wang, Keming Zhang
    Biomedicines.2023; 11(11): 2933.     CrossRef
  • Effectivity of Palliative Care Bundle on Advanced Gallbladder Cancer: A Randomised Controlled Trial
    Kusum K. Rohilla, C. Vasantha Kalyani, Amit Gupta, Manoj Gupta, Nirmal Matella
    Indian Journal of Palliative Care.2023; 29: 447.     CrossRef
  • Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature
    Wen-Hui Luo, Shao-Jun Li, Xue-Feng Wang
    World Journal of Gastrointestinal Oncology.2023; 15(11): 2033.     CrossRef
  • S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome
    M. Bitzer, S. Voesch, J. Albert, P. Bartenstein, W. Bechstein, S. Blödt, T. Brunner, F. Dombrowski, M. Evert, M. Follmann, C. La Fougère, P. Freudenberger, A. Geier, E. Gkika, M. Götz, E. Hammes, T. Helmberger, R. T. Hoffmann, W. P. Hofmann, P. Huppert, A
    Zeitschrift für Gastroenterologie.2022; 60(02): e186.     CrossRef
  • S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome
    M. Bitzer, S. Voesch, J. Albert, P. Bartenstein, W. Bechstein, S. Blödt, T. Brunner, F. Dombrowski, M. Evert, M. Follmann, C. La Fougère, P. Freudenberger, A. Geier, E. Gkika, M. Götz, E. Hammes, T. Helmberger, R. T. Hoffmann, W. P. Hofmann, P. Huppert, A
    Zeitschrift für Gastroenterologie.2022; 60(02): 219.     CrossRef
  • Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma
    Jianyang Fu, Nicole A McGrath, Jihye Lee, Xin Wang, Gagandeep Brar, Changqing Xie
    Hepatobiliary & Pancreatic Diseases International.2022; 21(5): 485.     CrossRef
  • Cytotoxic activities of ethanolic crude extracts from fruiting bodies of bamboo mushrooms (Dictyophora spp.) against cholangiocarcinoma cells
    Pathanin Chantree, Sirilak Chumkiew, Mantana Jamklang, Pongsakorn Martviset
    Research Results in Pharmacology.2022; 8(1): 33.     CrossRef
  • LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
    Eunsil Sung, Minkyung Ko, Ju-young Won, Yunju Jo, Eunyoung Park, Hyunjoo Kim, Eunji Choi, Ui-jung Jung, Jaehyoung Jeon, Youngkwang Kim, Hyejin Ahn, Da-som Choi, Seunghyun Choi, Youngeun Hong, Hyeyoung Park, Hanbyul Lee, Yong-Gyu Son, Kyeongsu Park, Jonghw
    Molecular Therapy.2022; 30(8): 2800.     CrossRef
  • Toripalimab in advanced biliary tract cancer
    Wei Li, Yueqi Wang, Yiyi Yu, Qian Li, Yan Wang, Chenlu Zhang, Xiaojing Xu, Xi Guo, Yu Dong, Yuehong Cui, Qing Hao, Lujia Huang, Houbao Liu, Tianshu Liu
    The Innovation.2022; 3(4): 100255.     CrossRef
  • Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy
    Sedighe Hosseini Shabanan, Nariman Nezami, Mohamed E. Abdelsalam, Rahul Anil Sheth, Bruno C. Odisio, Armeen Mahvash, Peiman Habibollahi
    Current Oncology.2022; 29(6): 3825.     CrossRef
  • Can patients with gallbladder adenocarcinoma and liver metastases obtain survival benefit from surgery? A population-based study
    Tianming Gao, Hua Tang, Baohuan Zhou, Dousheng Bai, Shengjie Jin, Chi Zhang, Guoqing Jiang
    Updates in Surgery.2022; 74(4): 1353.     CrossRef
  • Pharmacophore Based Design of Probable FGFR-1 Inhibitors from the 3D Crystal Structure of Infigratinib - A Drug Used in the Treatment of Cholangiocarcinomas
    Koushik Sarker , Avijit Ghosh , Abhijit Saha, Suvasish Mishra, Subrata Sen
    Letters in Drug Design & Discovery.2022; 19(4): 314.     CrossRef
  • Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways
    Michael J. Viereckl, Kelsey Krutsinger, Aaron Apawu, Jian Gu, Bryana Cardona, Donovan Barratt, Yuyan Han
    Biomolecules.2022; 12(6): 854.     CrossRef
  • Idiopathic hyperammonemic encephalopathy secondary to gemcitabine–cisplatin treatment
    Karlijn Verkerk, Hans-Martin Otten, Alwin D. R. Huitema
    Cancer Chemotherapy and Pharmacology.2022; 90(5): 417.     CrossRef
  • Enhanced gemcitabine cytotoxicity with knockdown of multidrug resistance protein genes in human cholangiocarcinoma cell lines
    Jiaqi Yang, David Sontag, Yuewen Gong, Gerald Y Minuk
    Journal of Gastroenterology and Hepatology.2021; 36(4): 1103.     CrossRef
  • Biliary tract cancer
    Juan W Valle, R Katie Kelley, Bruno Nervi, Do-Youn Oh, Andrew X Zhu
    The Lancet.2021; 397(10272): 428.     CrossRef
  • Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
    Changhoon Yoo, Sang Hyun Shin, Joon-Oh Park, Kyu-Pyo Kim, Jae Ho Jeong, Baek-Yeol Ryoo, Woohyung Lee, Ki-Byung Song, Dae-Wook Hwang, Jin-hong Park, Jae Hoon Lee
    Cancers.2021; 13(7): 1647.     CrossRef
  • Thoracoscopic metastasectomy is the method of choice in the stepwise treatment of disseminated cholangiocellular carcinoma
    A.A. Pechetov, A.V. Chzhao, Sh.V. Ragimov, D.A. Volchansky, M.A. Makov, B.N. Gurmikov
    Onkologiya. Zhurnal imeni P.A.Gertsena.2021; 10(2): 39.     CrossRef
  • IGF2BP1 IS A POOR PROGNOSTIC FACTOR IN EXTRAHEPATIC CHOLANGIOCARCINOMA
    Hung-Chune Maa, Yi-No Wu
    INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 80.     CrossRef
  • Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma
    Lynn E. Nooijen, Lotte C. Franken, Ali Belkouz, Ikrame Oulad Abdennabi, Marc G. Besselink, Olivier R. Busch, Rutger-Jan Swijnenburg, Heinz-Josef Klümpen, Joris I. Erdmann
    American Journal of Clinical Oncology.2021; 44(10): 526.     CrossRef
  • Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1
    Ranu S Sinniah, Mark S Shapses, Mohammad Umar Ahmed, Hani Babiker, Sreenivasa R. Chandana
    Expert Opinion on Investigational Drugs.2021; 30(10): 1047.     CrossRef
  • RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
    Jung Won Chun, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo
    Journal of Clinical Medicine.2021; 10(20): 4652.     CrossRef
  • Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR
    Yang Yang, Jigang Li, Lei Yao, Lile Wu
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
    Qiyi Zhang, Xingyu Liu, Shumei Wei, Lufei Zhang, Yang Tian, Zhenzhen Gao, Ming Jin, Sheng Yan
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Biliäre Karzinome: Zielstrukturen für eine molekulare Systemtherapie
    Sabrina Voesch, Michael Bitzer, Nisar Peter Malek
    Deutsches Ärzteblatt Online.2021;[Epub]     CrossRef
  • Treatment of advanced gallbladder cancer: A SEER‐based study
    Weipu Mao, Fang Deng, Dongyan Wang, Li Gao, Xiuquan Shi
    Cancer Medicine.2020; 9(1): 141.     CrossRef
  • LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma
    Sheng Shen, Jiwen Wang, Bohao Zheng, Ying Tao, Min Li, Yueqi Wang, Xiaoling Ni, Tao Suo, Houbao Liu, Han Liu, Jiwei Zhang
    Molecular Therapy - Nucleic Acids.2020; 19: 446.     CrossRef
  • Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
    Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai
    World Journal of Gastrointestinal Oncology.2020; 12(1): 83.     CrossRef
  • Low immune index correlates with favorable prognosis but with reduced benefit from chemotherapy in gallbladder cancer
    Jie Wang, Xiaobo Bo, Changcheng Wang, Yanlei Xin, Lingxi Nan, Rongkui Luo, Lingli Chen, Xiao Shi, Tao Suo, Xiaoling Ni, Han Liu, Sheng Shen, Min Li, Pinxiang Lu, Yueqi Wang, Houbao Liu
    Cancer Science.2020; 111(1): 219.     CrossRef
  • Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
    Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai
    World Journal of Gastrointestinal Oncology.2020; 12(1): 83.     CrossRef
  • Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer
    Mansi Arora, James M. Bogenberger, Amro Abdelrahman, Jennifer L. Leiting, Xianfeng Chen, Jan B. Egan, Aradhana Kasimsetty, Elzbieta Lenkiewicz, Smriti Malasi, Pedro Luiz Serrano Uson, Bolni Marius Nagalo, Yumei Zhou, Marcela A. Salomao, Heidi E. Kosiorek,
    Cancer Chemotherapy and Pharmacology.2020; 85(6): 1063.     CrossRef
  • NUC-1031 in biliary tract cancer: from bench to bedside and back?
    Lenka N. C. Boyd, Godefridus J. Peters, Geert Kazemier, Elisa Giovannetti
    Cancer Chemotherapy and Pharmacology.2020; 85(6): 1011.     CrossRef
  • Targeting cancer stem cells in cholangiocarcinoma (Review)
    Nicole Mcgrath, Jianyang Fu, Sophie Gu, Changqing Xie
    International Journal of Oncology.2020; 57(2): 397.     CrossRef
  • Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
    Makoto Ueno, Masafumi Ikeda, Takashi Sasaki, Fumio Nagashima, Nobumasa Mizuno, Satoshi Shimizu, Hiroki Ikezawa, Nozomi Hayata, Ryo Nakajima, Chigusa Morizane
    BMC Cancer.2020;[Epub]     CrossRef
  • Combined treatment for locally advanced cholangiocellular liver cancer - the case report
    A. N. Polyakov, Yu. I. Patyutko, A. Yu. Syskova, K. A. Romanova, I. S. Bazin, O. N. Sergeeva, E. R. Virshke, E. S. Makarov, E. Yu. Antonova, A. A. Kirshin, D. V. Podluzhnyi
    Research and Practical Medicine Journal.2019; 6(4): 158.     CrossRef
  • Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin
    J. Dierks, M. P. Gaspersz, A. Belkouz, J. L. A. van Vugt, R. J. S. Coelen, J. W. B. de Groot, A. J. ten Tije, W. G. Meijer, J. F. M. Pruijt, T. van Voorthuizen, D. J. van Spronsen, M. Rentinck, D. ten Oever, J. M. Smit, H. M. Otten, T. M. van Gulik, J. W.
    Acta Oncologica.2018; 57(6): 807.     CrossRef
  • Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy
    Jae Woo Lee, Yong-Tae Kim, Sang Hyub Lee, Jun Hyuk Son, Jin Woo Kang, Ji Kon Ryu, Dong Kee Jang, Woo Hyun Paik, Ban Seok Lee
    Gut and Liver.2018; 12(1): 102.     CrossRef
  • Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients
    Xiaobo Bo, Jie Wang, Tao Suo, Xiaoling Ni, Han Liu, Sheng Shen, Min Li, Yueqi Wang, Houbao Liu, Jiejie Xu
    BMC Cancer.2018;[Epub]     CrossRef
  • Revision of bilateral self-expandable metallic stents placed using the stent-in-stent technique for malignant hilar biliary obstruction
    Jun Hyuk Son, Hee Seung Lee, Sang Hyub Lee, Seungmin Bang, Jinwoo Kang, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim
    Hepatobiliary & Pancreatic Diseases International.2018; 17(5): 437.     CrossRef
  • Aktueller Therapiealgorithmus des intrahepatischen cholangiozellulären Karzinoms
    G. Lurje, J. Bednarsch, C. Roderburg, C. Trautwein, U. P. Neumann
    Der Chirurg.2018; 89(11): 858.     CrossRef
  • Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer
    Gaya Spolverato, Fabio Bagante, Cecilia G. Ethun, George Poultsides, Thuy Tran, Kamran Idrees, Chelsea A. Isom, Ryan C. Fields, Bradley Krasnick, Emily Winslow, Clifford Cho, Robert C. G. Martin, Charles R. Scoggins, Perry Shen, Harveshp D. Mogal, Carl Sc
    World Journal of Surgery.2017; 41(1): 224.     CrossRef
  • Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study
    Tulay Kus, Gokmen Aktas, Mehmet Emin Kalender, Alper Sevinc, Celaletdin Camci
    Journal of Gastrointestinal Cancer.2017; 48(2): 170.     CrossRef
  • SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts
    Changzheng Wang, Hongwei Lv, Wen Yang, Ting Li, Tian Fang, Guishuai Lv, Qin Han, Liwei Dong, Tianyi Jiang, Beige Jiang, Guangshun Yang, Hongyang Wang
    Cancer Letters.2017; 398: 1.     CrossRef
  • Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer
    Yoshiki Hirooka, Takuya Ishikawa, Hiroki Kawashima, Eizaburo Ohno, Koji Nonogaki, Akira Kanamori, Takanori Hirai, Hiroki Uchida, Osamu Shirai, Hideki Ishikawa, Hidemi Goto
    Cancer Chemotherapy and Pharmacology.2017; 80(1): 119.     CrossRef
  • CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
    Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang
    Cancer Research and Treatment.2017; 49(3): 807.     CrossRef
  • Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients
    Bum Jun Kim, Jaewon Hyung, Changhoon Yoo, Kyu-pyo Kim, Seong-Joon Park, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Jin-hong Park, Hyungwoo Cho, Baek-Yeol Ryoo, Heung-Moon Chang
    Cancer Chemotherapy and Pharmacology.2017; 80(1): 209.     CrossRef
  • Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis
    Jonghun John Lee, Sebastian T Schindera, Hyun-Jung Jang, Scott Fung, Tae Kyoung Kim
    Abdominal Radiology.2017; 42(12): 2898.     CrossRef
  • Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution
    Byoung Hyuck Kim, Eui Kyu Chie, Kyubo Kim, Jin-Young Jang, Sun Whe Kim, Do-Youn Oh, Yung-Jue Bang, Sung W. Ha
    Oncotarget.2017; 8(44): 78076.     CrossRef
  • The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis
    Xin-Fang Sun, Zhi-Kuan He, Jin-Ping Sun, Quan-Xing Ge, Er-Dong Shen
    Oncotarget.2017; 8(59): 100657.     CrossRef
  • Gemcitabine and cisplatin in inoperable, loco-regionally advanced and metastatic gallbladder cancer: A study from Northern India cancer institute
    Vineet Talwar, Shubhra Raina, Varun Goel, Dinesh C. Doval
    International Journal of Hepatobiliary and Pancreatic Diseases.2017; 7(2): 1.     CrossRef
  • Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
    Nai-Jung Chiang, Chiun Hsu, Jen-Shi Chen, Hsiao-Hui Tsou, Ying-Ying Shen, Yee Chao, Ming-Huang Chen, Ta-Sen Yeh, Yan-Shen Shan, Shiu-Feng Huang, Li-Tzong Chen
    Scientific Reports.2016;[Epub]     CrossRef
  • Chemotherapy for advanced biliary tract carcinoma
    Lawrence Chen, Chiehfeng Chen, Yun Yen, Ka-Wai Tam
    Medicine.2016; 95(33): e4584.     CrossRef
  • The role of microRNAs in gallbladder cancer
    GANGHUA YANG, LEI ZHANG, RUIXIANG LI, LIN WANG
    Molecular and Clinical Oncology.2016; 5(1): 7.     CrossRef
  • 18,229 View
  • 215 Download
  • 70 Web of Science
  • 66 Crossref
Close layer
Original Articles
Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer
Hyun Ae Jung, Hyun-Jun Kim, Chi Hoon Maeng, Se Hoon Park, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat. 2015;47(1):72-77.   Published online August 21, 2014
DOI: https://doi.org/10.4143/crt.2013.172
AbstractAbstract PDFPubReaderePub
Purpose
Capecitabine is known to increase mean corpuscular volume (MCV). To define the incidence of capecitabine-induced macrocytosis and its association with chemotherapy outcomes, we investigated data of 89 patients with advanced gastric cancer (AGC) who were enrolled in a randomized chemotherapy trial involving capecitabine. Materials and Methods Chemotherapy-naïve AGC patients were treated with capecitabine (1,000 mg/m2/day on days 1-14) plus cisplatin (75 mg/m2 on day 1), with or without epirubicin (50 mg/m2 on day 1). Complete blood counts including MCV were measured at baseline and on day 1 of each 3-week chemotherapy course. Macrocytosis was defined as a MCV increase > 10 fL from baseline. Multivariate Cox proportional hazards models were used for analysis of the impact of clinical and MCV values on chemotherapy outcomes. Results At baseline, the mean MCV was 88.2 fL (normal range, 80 to 100 fL). During chemotherapy, MCV increased in a dose-dependent manner with a mean increase of 11.3 fL. MCV elevation after capecitabine treatment in 74 patients (90%) and 44 patients (42%) developed macrocytosis. Results of multivariate analysis showed that development of macrocytosis was independent of baseline hemoglobin level, liver metastasis, performance status, or liver function. The number of chemotherapy cycles showed strong association with development of macrocytosis and hematologic adverse events. In addition, a significant association was observed between macrocytosis and clinical response or survival. Conclusion Macrocytosis developed with more frequent and prolonged use of capecitabine. It is possible that association with treatment outcomes warrants further investigation.

Citations

Citations to this article as recorded by  
  • Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment
    Gerd Jomrich, Maximilian Gruber, Elisabeth S. Gruber, Jakob Mühlbacher, Sanja Radosavljevic, Lavinia Wilfing, Daniel Winkler, Gerald Prager, Christian Reiterer, Barbara Kabon, Helmuth Haslacher, Klaus Sahora, Martin Schindl
    Journal of Visceral Surgery.2024; 161(2): 99.     CrossRef
  • Signification pronostique du volume globulaire moyen chez les patients ayant un traitement multimodal de l’adénocarcinome du pancréas
    Gerd Jomrich, Maximilian Gruber, Elisabeth S. Gruber, Jakob Mühlbacher, Sanja Radosavljevic, Lavinia Wilfing, Daniel Winkler, Gerald Prager, Christian Reiterer, Barbara Kabon, Helmuth Haslacher, Klaus Sahora, Martin Schindl
    Journal de Chirurgie Viscérale.2024; 161(2): 110.     CrossRef
  • The relevance of macrocytosis induction during neoadjuvant dose-dense chemotherapy in breast cancer patients
    Tihana Boraska Jelavić, Mario Podrug, Marija Ban, Ingrid Belac Lovasić, Zvonimir Curić, Eduard Vrdoljak
    Anti-Cancer Drugs.2022; 33(1): e655.     CrossRef
  • 5-Fluorouracil enhances the chemosensitivity of gastric cancer to TRAIL via inhibition of the MAPK pathway
    Hui Li, Jing Lv, Jing Guo, Shasha Wang, Shihai Liu, Yingji Ma, Zhiwei Liang, Yunyun Wang, Weiwei Qi, Wensheng Qiu
    Biochemical and Biophysical Research Communications.2021; 540: 108.     CrossRef
  • Platelet‐Lymphocyte ratio is a predictor for the development of no‐reflow phenomenon in patients with ST‐segment elevation myocardial infarction after thrombus aspiration
    Oktay ŞENÖZ, Sadık Volkan EMREN, Ahmet ERSEÇGİN, Zeynep YAPAN EMREN, İlker GÜL
    Journal of Clinical Laboratory Analysis.2021;[Epub]     CrossRef
  • Selected Hematological Biomarkers to Predict Acute Mortality in Emergency Department Patients. Recent Polish Hospital Statistics
    Katarzyna Brzeźniakiewicz-Janus, Marcus Daniel Lancé, Andrzej Tukiendorf, Tomasz Janus, Mirosław Franków, Joanna Rupa-Matysek, Zuzanna Walkowiak, Lidia Gil
    Disease Markers.2020; 2020: 1.     CrossRef
  • High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma
    Gerd Jomrich, Marlene Hollenstein, Max John, Robin Ristl, Matthias Paireder, Ivan Kristo, Reza Asari, Sebastian F. Schoppmann
    Annals of Surgical Oncology.2019; 26(4): 976.     CrossRef
  • The mean corpuscular volume as a prognostic factor for colorectal cancer
    Hidemasa Nagai, Norihiro Yuasa, Eiji Takeuchi, Hideo Miyake, Yuichiro Yoshioka, Kanji Miyata
    Surgery Today.2018; 48(2): 186.     CrossRef
  • Mean Corpuscular Volume as a Predictive Factor of Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer
    Wen-Yi Zhang, Xing-Xing Chen, Wen-Hao Chen, Hui Zhang, Chang-Lin Zou
    Gastroenterology Research and Practice.2018; 2018: 1.     CrossRef
  • The prognostic value of interaction between mean corpuscular volume and red cell distribution width in mortality in chronic kidney disease
    Chew-Teng Kor, Yao-Peng Hsieh, Chia-Chu Chang, Ping-Fang Chiu
    Scientific Reports.2018;[Epub]     CrossRef
  • Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel–carboplatin combination therapy in patients with epithelial ovarian cancer?
    Tihana Boraska Jelavić, Toni Boban, Luka Brčić, Eduard Vrdoljak
    Anti-Cancer Drugs.2017; 28(8): 922.     CrossRef
  • Mean Corpuscular Volume is a Prognostic Factor for Patients after Curative Resection for Stage II Colorectal Cancer
    Takahiro HOSOI, Norihiro YUASA, Eiji TAKEUCHI, Yasutomo GOTO, Hideo MIYAKE, Hidemasa NAGAI, Yuichiro YOSHIOKA, Kanji MIYATA
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2017; 78(5): 905.     CrossRef
  • Mean Corpuscular Volume and Mortality in Patients with CKD
    Yao-Peng Hsieh, Chia-Chu Chang, Chew-Teng Kor, Yu Yang, Yao-Ko Wen, Ping-Fang Chiu
    Clinical Journal of the American Society of Nephrology.2017; 12(2): 237.     CrossRef
  • Elevated red cell distribution width contributes to a poor prognosis in patients with esophageal carcinoma
    Guo-Xing Wan, Ping Chen, Xiao-Jun Cai, Lin-Jun Li, Xiong-Jie Yu, Dong-Feng Pan, Xian-He Wang, Xuan-Bin Wang, Feng-Jun Cao
    Clinica Chimica Acta.2016; 452: 199.     CrossRef
  • 12,285 View
  • 64 Download
  • 17 Web of Science
  • 14 Crossref
Close layer
Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
Kyung A Kwon, Sung Yong Oh, Ho Young Kim, Hyo Song Kim, Ha Young Lee, Tae Min Kim, Ho Yeong Lim, Na-Ri Lee, Hyo Jin Lee, Sook Hee Hong, Sun Young Rha
Cancer Res Treat. 2014;46(2):141-147.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.141
AbstractAbstract PDFPubReaderePub
Purpose

Collecting duct carcinoma (CDC) of the kidney is an aggressive disease with a poor prognosis, accountings for less than 1% of all renal cancers. To date, no standard therapy for CDC has been established. The aim of this study is an investigation of clinicopathologic findings of CDC and correlation of the disease status with a prognosis.

Materials and Methods

From 1996 to 2009, 35 patients with CDC were treated at eight medical centers. The diagnosis of CDC was made based on nephrectomy in 27 cases and renal biopsy in eight cases.

Results

Median PFS and OS for all patients were 5.8 months (95% CI 3.5 to 9.2) and 54.4 months (95% CI 0 to 109.2), respectively. The OS of patients with Stages I-III was 69.9 months (95% CI 54.0 to 85.8), while that of patients with Stage IV was 8.6 months (95% CI 0 to 23.3), which showed a statistically significant difference (p=0.01). In addition, among patients with Stage IV, the OS of patients who received a palliative treatment (immunotherapy, chemotherapy, or targeted therapy) was 18.4 months, which was higher than the OS of patients without treatment of 4.5 months.

Conclusion

CDC is a highly aggressive form of renal cell carcinoma. Despite most of the treatments, PFS and OS were short, however, there were some long-term survivors, therefore, conduct of additional research on the predictive markers of the several clinical, pathological differences and their treatments will be necessary.

Citations

Citations to this article as recorded by  
  • Collecting Duct Carcinoma: Characteristics and Survival outcomes from UroCCR database (CDCSurv UroCCR n°141)
    Dr Louis-Pacôme LE MEVEL, Pr Jean-Christophe BERNHARD, Dr Mokrane YACOUB, Dr Thibaut WAECKEL, Dr Céline BAZILLE, Dr Cécile CHAMPY, Dr Maria MAMODALY, Pr Karime BENSALAH, Pr Nathalie RIOUX-LECLERCQ, Dr Constance MICHEL, Dr Ilhem HERGLI, Dr Louis SURLEMONT,
    Clinical Genitourinary Cancer.2025; : 102305.     CrossRef
  • Urothelial Carcinoma of the Renal Pelvis with Synchronous Ipsilateral Collecting Duct Carcinoma: Two Case Reports
    Sang Bin Bae, Seong Kuk Yoon, Seo-hee Rha
    Journal of the Korean Society of Radiology.2024; 85(1): 222.     CrossRef
  • A curious case: Concurrent collecting duct renal cell carcinoma and upper tract urothelial carcinoma
    Adib Rahman, Daniel Matheson, Joanna Perry-Keene, Devang Desai
    Urology Case Reports.2024; 54: 102698.     CrossRef
  • Cancer subtype identification by multi-omics clustering based on interpretable feature and latent subspace learning
    Tianyi Shi, Xiucai Ye, Dong Huang, Tetsuya Sakurai
    Methods.2024; 231: 144.     CrossRef
  • Tumeurs de Bellini et carcinomes médullaires rénaux à l’ère des nouvelles thérapies
    Zoé Guillaume, Yves Allory, Edouard Auclin, Claire Gervais, Marie Auvray, Adrien Rochand, Arnaud Mejean, François Audenet, Yann-Alexandre Vano, Stéphane Oudard, Constance Thibault
    Bulletin du Cancer.2023; 110(4): 450.     CrossRef
  • Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
    Zoé Guillaume, Emeline Colomba, Jonathan Thouvenin, Carolina Saldana, Luca Campedel, Clément Dumont, Brigitte Laguerre, Denis Maillet, Cécile Vicier, Frédéric Rolland, Delphine Borchiellini, Philippe Barthelemy, Laurence Albiges, Edouard Auclin, Matthieu
    Cancers.2022; 14(7): 1678.     CrossRef
  • Uncommon malignant renal tumors and atypical presentation of common ones: a guide for radiologists
    Benjamin Laguna, Antonio C. Westphalen, C. T. Guimarães, Zhen Whang, Jeff Simko, Ronald Zagoria
    Abdominal Radiology.2019; 44(4): 1430.     CrossRef
  • Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH ‘Grupo Centro’ of Genitourinary Tumors
    A. Pinto, M. Garrido, C. Aguado, T. Alonso, P. Gajate, C. Maximiano, I. García-Carbonero, A. Martín, I. Gallegos, J.A. Arranz, J. Puente, E. Grande
    Kidney Cancer.2019; 3(3): 177.     CrossRef
  • Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
    Meghan Salgia, Jacob Adashek, Paulo Bergerot, Sumanta K. Pal
    Kidney Cancer.2017; 1(2): 99.     CrossRef
  • Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas
    Gabriel G. Malouf, Eva Compérat, Hui Yao, Roger Mouawad, Veronique Lindner, Nathalie Rioux-leclercq, Virginie Verkarre, Xavier Leroy, Linda Dainese, Marion Classe, Jean-Luc Descotes, Philippe Barthelemy, Mokrane Yacoub, Morgan Rouprêt, Jean-Christophe Ber
    Scientific Reports.2016;[Epub]     CrossRef
  • Clinical and computed tomography imaging features of renal medullary carcinoma: A report of six cases
    ZHENSHAN SHI, QIAN ZHUANG, RUIXIONG YOU, YUEMING LI, JIAN LI, DAIRONG CAO
    Oncology Letters.2016; 11(1): 261.     CrossRef
  • Collecting duct carcinoma of the kidney is associated withCDKN2Adeletion andSLCfamily gene up-regulation
    Jianmin Wang, Antonios Papanicolau-Sengos, Sreenivasulu Chintala, Lei Wei, Biao Liu, Qiang Hu, Kiersten Marie Miles, Jeffrey M. Conroy, Sean T. Glenn, Manuela Costantini, Cristina Magi-Galluzzi, Sabina Signoretti, Toni Choueiri, Michele Gallucci, Steno Se
    Oncotarget.2016; 7(21): 29901.     CrossRef
  • 11,972 View
  • 73 Download
  • 15 Web of Science
  • 12 Crossref
Close layer
A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience
Soon Il Lee, Se Hoon Park, Do Hyoung Lim, Keon Woo Park, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat. 2011;43(2):96-101.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.96
AbstractAbstract PDFPubReaderePub
PURPOSE
Fluoropyrimidine-based combination chemotherapy, in combination with either oxaliplatin or irinotecan, has demonstrated efficacy and tolerability in treatment of advanced colorectal cancer (ACC).
MATERIALS AND METHODS
Between January 2006 and December 2007, a total of 478 ACC patients were treated with combination chemotherapy in first-line settings. Combination therapies included: 5-fluorouracil, folinic acid plus oxaliplatin (FOLFOX, n=172), 5-fluorouracil, folinic acid plus irinotecan (FOLFIRI, n=95), capecitabine plus oxaliplatin (XELOX, n=155), and capecitabine plus irinotecan (XELIRI, n=56). FOLFOX and FOLFIRI were repeated every 2 weeks, whereas XELOX and XELIRI were repeated every 3 weeks until occurrence of disease progression or unacceptable toxicity, or until a patient chose to discontinue treatment.
RESULTS
The median age was 58 years (range, 19 to 84 years) and the median chemotherapy durations for FOLFOX, FOLFIRI, XELOX, and XELIRI were 4.9, 4.5, 5.7, and 5.4 months, respectively. Combination chemotherapy regimens were generally well tolerated. The estimated median progression-free-survival (PFS) for all patients was 6.8 months (95% confidence interval, 6.3 to 7.3 months). No statistically significant difference in PFS was found among regimens used as first-line chemotherapy. Sixty percent (n=290) of patients received second or further lines of therapy after failure.
CONCLUSION
Fluoropyrimidine-based combination chemotherapy regimens appear to be equally active and tolerable as first-line therapy for ACC.

Citations

Citations to this article as recorded by  
  • Nineteen-year, real-world experience of first-line combination chemotherapy in patients with metastatic colorectal cancer: a propensity score analysis from southern Thailand
    Jirapat Wonglhow, Chirawadee Sathitruangsak, Arunee Dechaphunkul, Patrapim Sunpaweravong
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer
    Si-Qi Dong, Tong-Min Wang, Jiang-Bo Zhang, Yong-Qiao He, Wen-Qiong Xue, Zi-Yi Wu, Da-Wei Yang, Lian-Jing Cao, Jing-Wen Huang, Xi-Zhao Li, Pei-Fen Zhang, Xiao-Hui Zheng, Wei-Hua Jia
    Cancer Research and Treatment.2021; 53(3): 724.     CrossRef
  • 10,553 View
  • 75 Download
  • 2 Crossref
Close layer
Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer
Kyung Kee Baek, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Ho-Kyung Chun
Cancer Res Treat. 2010;42(4):185-190.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.185
AbstractAbstract PDFPubReaderePub
Purpose

Oxaliplatin-induced chronic peripheral neurotoxicity (OXCPN) manifests as a loss of sensation and dysesthesia in the distal extremities, which may impair daily activities and increase in incidence with the amount of oxaliplatin delivered. The variation in the reported incidence and severity of OXCPN may be a consequence of differences in the baseline characteristics of patients.

Materials and Methods

This was a prospective study (ClinicalTrials.gov, NCT00977717) in which OXCPN was recorded for all consecutive colon cancer patients treated at Samsung Medical Center (Seoul, Korea) with oxaliplatin-based combination chemotherapy. The primary endpoint was the incidence of severe OXCPN (grade 2 lasting for >7 days, or grade 3). The association of severe OXCPN and pretreatment parameters was evaluated using a multivariate regression model.

Results

Between Jan 2008 and Feb 2010, 100 patients treated with adjuvant folinic acid/fluorouracil plus oxaliplatin (FOLFOX) and 266 patients treated with capecitabine plus oxaliplatin (XELOX) or FOLFOX for advanced disease were registered into our study. The median cumulative dose of oxaliplatin was 796 mg/m2 (range, 85 to 1,583 mg/m2). Severe OXCPN was observed in 126 (34%) patients. Overall, 43 patients discontinued chemotherapy due to toxicity: 23 without severe OXCPN and 20 with severe OXCPN. In univariate analysis, severe OXCPN was frequently observed in patients with age ≥55 years (p<0.01), stage II or III (p<0.01), adjuvant setting (p=0.01), FOLFOX (p<0.01), performance status of 0 (p=0.02), and those with no prior chemotherapy (p<0.01). In a multivariate regression model, the number of chemotherapy cycles and the cumulative oxaliplatin dose were not associated with the development of severe OXCPN.

Conclusion

We failed to find a significant association between patient characteristics at baseline and the development of severe OXCPN after oxaliplatin-based combination chemotherapy. Pharmacogenomic profiling using genome-wide association study in these patients is underway.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of traditional plant-based medicines for preventing chronic oxaliplatin-induced peripheral neurotoxicity in patients with colorectal cancer: A systematic review and meta-analysis with core herb contribution
    Jierong Han, Hengzhou Lai, Wenyuan Li, Huarui Liao, Chong Xiao, Xueke Li, Fengming You, Jing Guo
    Journal of Ethnopharmacology.2024; 326: 117735.     CrossRef
  • Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment
    Zhe Li, Xin Qiao, Xiao-Meng Liu, Shu-Hao Shi, Xin Qiao, Jing-Yuan Xu
    European Journal of Medicinal Chemistry.2023; 250: 115233.     CrossRef
  • Adjuvant Chemotherapy in pT2N0M0 Gastric Cancer: Findings From a Retrospective Study
    Yu Mei, Xijia Feng, Tienan Feng, Min Yan, Zhenggang Zhu, Tian Li, Zhenglun Zhu
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
    Roser Velasco, Montserrat Alemany, Macarena Villagrán, Andreas A. Argyriou
    Journal of Personalized Medicine.2021; 11(7): 669.     CrossRef
  • The Incidence of Oxaliplatin-Induced Peripheral Neurotoxicity at Khartoum Oncology Hospital: A Cross-Sectional Survey
    Nadeen T Ali, Amel A Mohamed, Bashir A Yousef
    Asia-Pacific Journal of Oncology Nursing.2020; 7(3): 266.     CrossRef
  • Clinical pharmacology of oncology agents in older adults: A comprehensive review of how chronologic and functional age can influence treatment-related effects
    Ginah Nightingale, Rowena Schwartz, Ekaterina Kachur, Brianne N. Dixon, Christine Cote, Ashley Barlow, Brooke Barlow, Patrick Medina
    Journal of Geriatric Oncology.2019; 10(1): 4.     CrossRef
  • Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial
    Se Hoon Park, Jeeyun Lee, Tae Sung Sohn, Do Hoon Lim, Kyoung-Mee Kim, Ji Yeong An, Min Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Kim, Su Jin Lee, Seung Tae Kim, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
    Precision and Future Medicine.2019; 3(1): 24.     CrossRef
  • Oxaliplatin‐induced enteric neuronal loss and intestinal dysfunction is prevented by co‐treatment with BGP‐15
    Rachel M McQuade, Vanesa Stojanovska, Rhian Stavely, Cara Timpani, Aaron C Petersen, Raquel Abalo, Joel C Bornstein, Emma Rybalka, Kulmira Nurgali
    British Journal of Pharmacology.2018; 175(4): 656.     CrossRef
  • Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients
    Akie Watanabe, Chang Cheng Yang, Winson Y. Cheung
    Medical Oncology.2018;[Epub]     CrossRef
  • Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin‐induced peripheral neuropathy in Taiwanese patients with colorectal cancer
    Shu‐Yi Hsu, Wen‐Shih Huang, Shu‐Hui Lee, Tsui‐Ping Chu, Yung‐Chang Lin, Chang‐Hsien Lu, Randal D. Beaton, Sui‐Whi Jane
    European Journal of Cancer Care.2018; : e12976.     CrossRef
  • Factors associated with the development and severity of oxaliplatin‐induced peripheral neuropathy: a systematic review
    Jeremy N. Pulvers, Gavin Marx
    Asia-Pacific Journal of Clinical Oncology.2017; 13(6): 345.     CrossRef
  • Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy
    Kelly A Aromolaran, Peter A Goldstein
    Molecular Pain.2017;[Epub]     CrossRef
  • ALA-induced photodynamic effect on vitality, apoptosis, and secretion of vascular endothelial growth factor (VEGF) by colon cancer cells in normoxic environment in vitro
    A. Kawczyk-Krupka, K. Sieroń-Stołtny, W. Latos, Z.P. Czuba, B. Kwiatek, M. Potempa, K. Wasilewska, W. Król, A. Stanek
    Photodiagnosis and Photodynamic Therapy.2016; 13: 308.     CrossRef
  • ALA-induced photodynamic effect on viability, apoptosis and secretion of S100 protein, secreted by colon cancer cells in vitro
    Aleksandra Kawczyk-Krupka, Wojciech Latos, Magdalena Latos, Zenon P. Czuba, Aleksander Sieroń
    Photodiagnosis and Photodynamic Therapy.2016; 15: 218.     CrossRef
  • ALA-mediated photodynamic effect on apoptosis induction and secretion of macrophage migration inhibitory factor (MIF) and of monocyte chemotactic protein (MCP-1) by colon cancer cells in normoxia and in hypoxia-like conditions in vitro
    Aleksandra Kawczyk-Krupka, Andrzej M. Bugaj, Wojciech Latos, Katarzyna Wawrzyniec, Piotr Oleś, Anna Mertas, Zenon Czuba, Wojciech Król, Karolina Sieroń-Stołtny, Aleksander Sieroń
    Photodiagnosis and Photodynamic Therapy.2015; 12(1): 27.     CrossRef
  • The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy
    Joanna E. Fardell, Janette Vardy, Lauren A. Monds, Ian N. Johnston
    Behavioural Brain Research.2015; 291: 80.     CrossRef
  • Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN)
    Andreas Argyriou
    Toxics.2015; 3(2): 187.     CrossRef
  • α7 Nicotinic Receptor Promotes the Neuroprotective Functions of Astrocytes against Oxaliplatin Neurotoxicity
    Lorenzo Di Cesare Mannelli, Barbara Tenci, Matteo Zanardelli, Paola Failli, Carla Ghelardini
    Neural Plasticity.2015; 2015: 1.     CrossRef
  • Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran
    Ali Shahriari-Ahmadi, Ali Fahimi, Mehrdad Payandeh, Masoud Sadeghi
    Asian Pacific Journal of Cancer Prevention.2015; 16(17): 7603.     CrossRef
  • Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
    R. Velasco, J. Bruna, C. Briani, A. A. Argyriou, G. Cavaletti, P. Alberti, B. Frigeni, M. Cacciavillani, S. Lonardi, D. Cortinovis, M. Cazzaniga, C. Santos, H. P. Kalofonos
    Journal of Neurology, Neurosurgery & Psychiatry.2014; 85(4): 392.     CrossRef
  • Chemotherapy-induced neuropathy: A comprehensive survey
    N.C. Miltenburg, W. Boogerd
    Cancer Treatment Reviews.2014; 40(7): 872.     CrossRef
  • Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study
    A. Custodio, J. Moreno-Rubio, J. Aparicio, J. Gallego-Plazas, R. Yaya, J. Maurel, O. Higuera, E. Burgos, D. Ramos, A. Calatrava, E. Andrada, R. López, V. Moreno, R. Madero, P. Cejas, J. Feliu
    Annals of Oncology.2014; 25(2): 398.     CrossRef
  • Oxaliplatin Neurotoxicity
    Roser Velasco, Jordi Bruna
    Current Colorectal Cancer Reports.2014; 10(3): 303.     CrossRef
  • Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects
    Rachel M. McQuade, Joel C. Bornstein, Kulmira Nurgali
    International Journal of Clinical Medicine.2014; 05(07): 393.     CrossRef
  • Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study
    Jenny E. Drott, Hans Starkhammar, Sussanne Börjeson, Carina M. Berterö
    Open Journal of Nursing.2014; 04(04): 265.     CrossRef
  • Advanced age and liability to oxaliplatin‐induced peripheral neuropathy: post hoc analysis of a prospective study
    A. A. Argyriou, C. Briani, G. Cavaletti, J. Bruna, P. Alberti, R. Velasco, S. Lonardi, D. Cortinovis, M. Cazzaniga, M. Campagnolo, C. Santos, H. P. Kalofonos
    European Journal of Neurology.2013; 20(5): 788.     CrossRef
  • Neuropatia Periférica em Pacientes com Câncer Colorretal em Tratamento com Oxaliplatina
    Helena Maria de Cerqueira Mathias, Maria Cecília Mathias Machado, Adriano Celso Rodrigues
    Revista Neurociências.2013; 21(3): 435.     CrossRef
  • Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients
    Hong‐Hee Won, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jong‐Won Kim, Soo‐Youn Lee, Se Hoon Park
    Cancer.2012; 118(11): 2828.     CrossRef
  • Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients
    A.A. Argyriou, R. Velasco, C. Briani, G. Cavaletti, J. Bruna, P. Alberti, M. Cacciavillani, S. Lonardi, C. Santos, D. Cortinovis, M. Cazzaniga, H.P. Kalofonos
    Annals of Oncology.2012; 23(12): 3116.     CrossRef
  • Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial
    R. X. Zhang, Z. H. Lu, D. S. Wan, X. J. Wu, P. R. Ding, L. H. Kong, Z. Z. Pan, G. Chen
    International Journal of Colorectal Disease.2012; 27(12): 1645.     CrossRef
  • 12,285 View
  • 81 Download
  • 30 Crossref
Close layer
Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy
Jina Yun, Kyoung-Mee Kim, Seung Tae Kim, Jung-Hoon Kim, Jung A Kim, Jee Hyun Kong, Soo Hyeon Lee, Young-Woong Won, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat. 2010;42(2):101-106.   Published online June 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.2.101
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to determine whether the ERCC1 expression is effective to predict the clinical outcomes of patients with advanced gastric cancer (AGC) and who were treated with cisplatin-based first-line chemotherapy.

Materials and Methods

A total of 89 measurable AGC patients received cisplatin and capecitabine, with or without epirubicin, as a part of a randomized phase II study. Patients were included for the current molecular analysis if they had received two or more cycles of chemotherapy, their objective tumor responses were measured and if their paraffin-embedded tumor samples were available. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and the patients were divided into two groups (positive or negative) according to the presence of IHC staining of the tumor cell nuclei.

Results

Of the 32 eligible patients, 21 patients (66%) had tumor with a positive expression of ERCC1 and the remaining 11 patients had tumor with a negative ERCC1-expression. The ERCC1-negative patients achieved a higher response rate than that of the ERCC1-positive patients (44% vs. 28%, respectively), although the difference was not statistically significant (p=0.42). The median survival time for the all patients was 14.6 months (95% CI: 13.6 to 15.6 months). The one-year survival rate was similar for the ERCC1-negative patients (61%) and the ERCC1-positive patients (70%).

Conclusion

In the current study, the tumor ERCC1 expression by IHC staining could not predict the clinical response or survival of AGC patients who were treated with cisplatin-based first-line chemotherapy. The ERCC1 protein expression does not appear to be a useful tool for the selection of tailored chemotherapy for these patients.

Citations

Citations to this article as recorded by  
  • Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review
    Eduardo Henrique Cunha Neves Filho, Rosane Oliveira de Sant'Ana, Luiz Vianney Saldanha Cidrão Nunes, Adriana Pinheiro Bezerra Pires, Maria do Perpétuo Socorro Saldanha da Cunha
    APMIS.2017; 125(2): 79.     CrossRef
  • Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine
    Shalong Wang, Lianwen Yuan
    BioScience Trends.2016; 10(3): 171.     CrossRef
  • Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
    Zheng-mao Lu, Tian-hang Luo, Ming-ming Nie, Guo-en Fang, Li-ye Ma, Xu-chao Xue, Guo Wei, Chong-we Ke, Jian-wei Bi
    Tumor Biology.2014; 35(4): 2941.     CrossRef
  • The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
    Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan
    Tumor Biology.2014; 35(9): 8721.     CrossRef
  • Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
    Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
    Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2107.     CrossRef
  • Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term
    Liqi Chen, Guoli Li, Jieshou Li, Chaogang Fan, Jian Xu, Bo Wu, Kun Liu, Caihua Zhang
    Cancer Chemotherapy and Pharmacology.2013; 71(4): 921.     CrossRef
  • ERCC1 C19007T polymorphism and the risk and invasiveness of cervical cancer in Korean women
    Seung‐Su HAN, Jae Weon KIM, Sang Hoon LEE, Dong Ho KIM, Noh‐Hyun PARK, Yong‐Sang SONG, Soon‐Beom KANG
    Asia-Pacific Journal of Clinical Oncology.2012;[Epub]     CrossRef
  • Gastric Cancer
    Joshua D. Lawson, Jason K. Sicklick, Paul T. Fanta
    Current Problems in Cancer.2011; 35(3): 97.     CrossRef
  • 10,140 View
  • 42 Download
  • 8 Crossref
Close layer
Case Report
TTP-HUS Associated with Sunitinib
Moon Ki Choi, Jung Yong Hong, Jun Ho Jang, Ho Yeong Lim
Cancer Res Treat. 2008;40(4):211-213.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.211
AbstractAbstract PDFPubReaderePub

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare condition that is severe and may be fatal. Adverse reactions to drugs increasingly are reported as probable causes of TTP-HUS. Many chemotherapeutic agents have also been implicated in causing TTP-HUS. We reported a woman with metastatic renal cell carcinoma who presented with TTP-HUS associated with sunitinib. She had gross hematuria and generalized edema. The hemoglobin concentration was 8.9 g/dl and the platelet count was 46,000/mm3. Her reticulocyte count was increased to 4.1% and the peripheral blood smear revealed red blood cell fragmentation and spherocytes. The patient completely recovered after discontinuing the use of sunitinib and undergoing plasmapheresis. Because of the increasing use of sunitinib in the treatment of cancer patients, oncologists should be aware of the possibility of TTP-HUS related to sunitinib, as early recognition and prompt therapeutic intervention can be beneficial.

Citations

Citations to this article as recorded by  
  • Chemotherapy and hemostasis disorders
    E. V. Slukhanchuk, V. O. Bitsadze, A. G. Solopova, J. Kh. Khizroeva, K. N. Grigoreva, N. R. Gashimova, N. A. Makatsariya, D. V. Blinov, V. N. Galkin, A. Yu. Shatilina, E. M. Lyadnova, N. A. Shulga, L. T. Toguzaeva, S. Morkos, J.-C. Gris, I. Elalamy, G. Ge
    Obstetrics, Gynecology and Reproduction.2025; 18(6): 835.     CrossRef
  • Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy
    Anukul Ghimire, Rebecca Brassington, Kim Solez, Aminu Bello
    BMJ Case Reports.2024; 17(1): e255841.     CrossRef
  • Nonthrombocytopenic, noninflammatory simplex purpura during sunitinib therapy
    Marta García‐Legaz Martínez, Álvaro Martínez‐Doménech, Gemma Pérez‐Pastor, Jorge Magdaleno‐Tapial, Cristian Valenzuela‐Oñate, Víctor Alegre‐de Miquel, Amparo Pérez‐Ferriols
    International Journal of Dermatology.2019;[Epub]     CrossRef
  • Thrombotic microangiopathy in cancer patients
    Alexander D. Makatsariya, Ismail Elalamy, Alexander V. Vorobev, Angelina S. Bakhtina, Muyang Meng, Victoria O. Bitsadze, Jamilya Kh. Khizroeva
    Annals of the Russian academy of medical sciences.2019; 74(5): 323.     CrossRef
  • Thrombotic microangiopathy in cancer
    Ilene Ceil Weitz
    Thrombosis Research.2018; 164: S103.     CrossRef
  • Cancer drugs and the glomerulus
    Hitesh H Shah, Nupur N Uppal, Mark A Perazella
    Journal of Onco-Nephrology.2018; 2(2-3): 78.     CrossRef
  • Therapeutic Plasma Exchange and Its Impact on Drug Levels
    Caleb W Cheng, Jeanne E Hendrickson, Christopher A Tormey, Davinder Sidhu
    American Journal of Clinical Pathology.2017; 148(3): 190.     CrossRef
  • Thrombotic Microangiopathy, Cancer, and Cancer Drugs
    Hassan Izzedine, Mark A. Perazella
    American Journal of Kidney Diseases.2015; 66(5): 857.     CrossRef
  • Sunitinib-associated Thrombotic Microangiopathy: A Significant Risk
    F.D. Buckley, G. Preston, D.J. Meiklejohn, D. Adamson
    Clinical Oncology.2014; 26(8): 515.     CrossRef
  • Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature
    Rebecca L. Ruebner, Lawrence Copelovitch, Nicholas F. Evageliou, Michelle R. Denburg, Jean B. Belasco, Bernard S. Kaplan
    Pediatric Nephrology.2014; 29(5): 863.     CrossRef
  • Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
    Liliane Hobeika, Sally E Self, Juan Carlos Q Velez
    BMC Nephrology.2014;[Epub]     CrossRef
  • Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature
    Imane El Dika, Deborah Mukherji, Sally Temraz, Rita Assi, Ali Shamseddine
    Case Reports in Medicine.2014; 2014: 1.     CrossRef
  • Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor
    Hasan Mutlu, Abdullah Büyükçelik, Zeki Akça, Nilgün Kaya
    Journal of Oncology Pharmacy Practice.2014; 20(4): 298.     CrossRef
  • A Case of Sunitinib-Associated Thrombotic Thrombocytopenic Purpura
    Eun Jin Kim, Yun Mi Choi, Sin Won Lee, Yeon Jung Ha, Jae Lyun Lee
    Korean Journal of Medicine.2013; 84(2): 303.     CrossRef
  • Thrombotic Microangiopathy Associated with Bortezomib Treatment in a Patient with Relapsed Multiple Myeloma
    Urpu Salmenniemi, Kari Remes
    Hematology Reports.2012; 4(2): e13.     CrossRef
  • Hematologic toxicities of small molecule tyrosine kinase inhibitors
    Nicholas A. Barber, Wais Afzal, Mojtaba Akhtari
    Targeted Oncology.2011; 6(4): 203.     CrossRef
  • Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
    H. Izzedine, C. Massard, J. C. Soria
    Clinical Kidney Journal.2011; 4(1): 78.     CrossRef
  • Docetaxel-Induced Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome–Related Complex in a Patient With Metastatic Prostate Cancer?
    Anuj Shrestha, Pam Khosla, Yunfei Wei
    American Journal of Therapeutics.2011; 18(5): e167.     CrossRef
  • Micafungin-Induced Thrombotic Thrombocytopenic Purpura: A Case Report and Review of the Literature
    Maisa Nazzal, Fadi Safi, Freda Arma, Mustafa Nazzal, Mahvish Muzaffar, Ragheb Assaly
    American Journal of Therapeutics.2011; 18(6): e258.     CrossRef
  • Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
    Min Hee Hong, Hyo Song Kim, Chan Kim, Jung Ryun Ahn, Hong Jae Chon, Sang-Joon Shin, Joong-Bae Ahn, Hyun Cheol Chung, Sun Young Rha
    Cancer Research and Treatment.2009; 41(2): 67.     CrossRef
  • 10,616 View
  • 65 Download
  • 20 Crossref
Close layer
Original Articles
Mouse Orthotopic Lung Cancer Model Induced by PC14PE6
Zheng Yun Cui, Jin Seok Ahn, Jee Yun Lee, Won Seog Kim, Ho Yeong Lim, Hyun Jung Jeon, Soo Won Suh, Jin Hoon Kim, Won Ho Kong, Ji Min Kang, Do Hyun Nam, Keunchil Park
Cancer Res Treat. 2006;38(4):234-239.   Published online December 31, 2006
DOI: https://doi.org/10.4143/crt.2006.38.4.234
AbstractAbstract PDFPubReaderePub
Purpose

This study was undertaken to investigate in detail the xenograft mouse orthotopic lung cancer model induced by PC14PE6 adenocarcinoma cells.

Materials and Methods

Three cell doses (0.5×106; 1×106; 2×106) of PC14PE6 cells were injected into the lungs of male BALB/c nude mice by the intrathoracic injection method. The lung and other organs, including brain, liver, spleen, kidney, muscle, adrenal gland, and lymph node on knee, were removed and stained with H/E to detect the presence of tumor cells.

Results

The reliable tumorigenicity time in the PC14PE6 adenocarcinoma cell-inoculated BALB/c nude mouse was 10 days after intrathoracic injection. The average life span of the three groups after inoculation was 14 days in the 2×106 cells inoculum group; 25 days in the 1×106 cells inoculum group; and 32 days in the 0.5×106 cells inoculum group. The PC14PE6 adenocarcinoma cells induced orthotopic lung cancer limited within the thorax.

Conclusions

This orthotopic lung cancer model is an efficient cancer model with easy inoculation methods, rapid and high tumorigenicity, and simple monitoring methods for metastasis.

Citations

Citations to this article as recorded by  
  • Actin-Dependent Mechanism of Tumor Progression Induced by a Dysfunction of p53 Tumor Suppressor
    Natalia Khromova, Maria Vasileva, Vera Dugina, Dmitry Kudlay, Peter Chumakov, Sergei Boichuk, Pavel Kopnin
    Cancers.2024; 16(6): 1123.     CrossRef
  • Immuno-PET Imaging of EGFR with 64Cu-NOTA Panitumumab in Subcutaneous and Metastatic Nonsmall Cell Lung Cancer Xenografts
    Nasim Sarrami, Melinda Wuest, Igor Moura de Paiva, Samantha Leier, Afsaneh Lavasanifar, Frank Wuest
    Molecular Pharmaceutics.2024; 21(11): 5797.     CrossRef
  • Targets, Mechanisms and Cytotoxicity of Half-Sandwich Ir(III) Complexes Are Modulated by Structural Modifications on the Benzazole Ancillary Ligand
    M. Isabel Acuña, Ana R. Rubio, Marta Martínez-Alonso, Natalia Busto, Ana María Rodríguez, Nerea Davila-Ferreira, Carl Smythe, Gustavo Espino, Begoña García, Fernando Domínguez
    Cancers.2022; 15(1): 107.     CrossRef
  • Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment
    Ulrich Jarry, Mégane Bostoën, Raphaël Pineau, Laura Chaillot, Valentine Mennessier, Pierre Montagne, Emilie Motte, Marjorie Gournay, Arnaud Le Goff, Thierry Guillaudeux, Rémy Pedeux
    BMC Cancer.2021;[Epub]     CrossRef
  • Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula as therapeutics to non-small cell lung carcinoma acting via Rap1/cdc42 signaling: A transcriptomics/ bio-informatics biological validation approach
    Hor-Yue Tan, Venice Wing-Tung Ho, Yau-Tuen Chan, Cheng Zhang, Ning Wang, Wen Xia, Yibin Feng
    Pharmacological Research.2020; 155: 104415.     CrossRef
  • Metastatic Spread from Abdominal Tumor Cells to Parathymic Lymph Nodes
    Gábor Király, Zoltán Hargitai, Ilona Kovács, Gábor Szemán-Nagy, István Juhász, Gáspár Bánfalvi
    Pathology & Oncology Research.2019; 25(2): 625.     CrossRef
  • LPP inhibits collective cell migration during lung cancer dissemination
    S Kuriyama, M Yoshida, S Yano, N Aiba, T Kohno, Y Minamiya, A Goto, M Tanaka
    Oncogene.2016; 35(8): 952.     CrossRef
  • Docetaxel-loaded polyglutamic acid-PEG nanocapsules for the treatment of metastatic cancer
    Erea Borrajo, Raquel Abellan-Pose, Atenea Soto, Marcos Garcia-Fuentes, Noemi Csaba, Maria J. Alonso, Anxo Vidal
    Journal of Controlled Release.2016; 238: 263.     CrossRef
  • Targeting p300 Addiction inCBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation ofMYCExpression
    Hideaki Ogiwara, Mariko Sasaki, Takafumi Mitachi, Takahiro Oike, Saito Higuchi, Yuichi Tominaga, Takashi Kohno
    Cancer Discovery.2016; 6(4): 430.     CrossRef
  • Effects of transplantation sites on tumour growth, pulmonary metastasis and ezrin expression of canine osteosarcoma cell lines in nude mice
    T. Jaroensong, Y. Endo, S.‐J. Lee, A. Kamida, M. Mochizuki, R. Nishimura, N. Sasaki, T. Nakagawa
    Veterinary and Comparative Oncology.2012; 10(4): 274.     CrossRef
  • A Novel Bioluminescence Orthotopic Mouse Model for Advanced Lung Cancer
    Bo Li, Artour Torossian, Wenyan Li, Stephen Schleicher, Kathy Niu, Nicholas J. Giacalone, Sung June Kim, Heidi Chen, Adriana Gonzalez, Luigi Moretti, Bo Lu
    Radiation Research.2011; 176(4): 486.     CrossRef
  • Small Azurin Derived Peptide Targets Ephrin Receptors for Radiotherapy
    Ewa D. Micewicz, Chun-Ling Jung, Dorthe Schaue, Hai Luong, William H. McBride, Piotr Ruchala
    International Journal of Peptide Research and Therapeutics.2011; 17(3): 247.     CrossRef
  • The Incidence Rate and Severity of Orthotopic Lung Cancer in an Animal Model Depends on the Number of A549 Cells and Transplantation Period
    Jinsoo Lee, Young-Ah Han, Hyo-Seon Yang, Jeong-Ah Song, Young-Su Yang, Soonjin Kwon, Min-Sung Kang, Kyuhong Lee, Jeong-Doo Heo, Kyu-Hyuk Cho, Chang Woo Song
    Laboratory Animal Research.2010; 26(4): 369.     CrossRef
  • Tumorigenesis after Injection of Lung Cancer Cell Line (SW-900 G IV) into the Pleural Cavity of Nude Mice
    Eok-Sung Park, Song-Myung Kim, Jong-In Kim
    The Korean Journal of Thoracic and Cardiovascular Surgery.2010; 43(6): 588.     CrossRef
  • Modest Anti-Cancer Activity of a Bile Acid Acylated Heparin Derivative in a PC14PE6 Induced Orthotopic Lung Cancer Model
    Zheng Yun Cui, Min Jae Park, Jeeyun Lee, Jin Seok Ahn, Myung Ju Ahn, Soo Won Seo, Jin Woo Park, Youngro Byun, Keunchil Park
    Cancer Research and Treatment.2009; 41(2): 80.     CrossRef
  • 16,252 View
  • 127 Download
  • 15 Crossref
Close layer
Multidimensional Constructs of the EORTC Quality of Life Questionnaire (QLQ-C30) in Korean Cancer Patients with Heterogeneous Diagnoses
Eun-Hyun Lee, Mison Chun, Hee-Jung Wang, Ho Yeong Lim, Jin-Hyuk Choi
Cancer Res Treat. 2005;37(3):148-156.   Published online June 30, 2005
DOI: https://doi.org/10.4143/crt.2005.37.3.148
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to evaluate the multidimensional constructs of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with cancer, employing not only the commonly used multitrait scaling analysis and interscale correlations, but also the factorial and multidimensional scaling (MDS) analyses.

Materials and Methods

A total of 334 Korean cancer patients participated in this cross-sectional study. All patients completed the QLQ-C30.

Results

With the multitrait scaling analysis, the cognitive functioning scale did not meet item convergent and divergent validities. With the interscale correlations, the physical and role functioning scales were found to be highly correlated; this was also evident in the factorial analysis. The MDS showed that each item within the social, emotional, global health status/quality of life, and nausea/vomiting scales were clustered close together, but far from those of the other scales.

Conclusion

The authors conclude that the four way evaluation of the QLQ-C30 produced results that supported the original hypothesized constructs. However, the physical and role functioning scales were not distinctive, and that of the cognitive functioning was somewhat problematic in the Korean population with cancer.

Citations

Citations to this article as recorded by  
  • Validation of Gujarati Version of European Organization for Research and Treatment of Cancer Quality of Life Modules in Head and Neck Cancer Patients of Western India
    Sujal Parkar, Abhishek Sharma, Mihir Shah
    Indian Journal of Otolaryngology and Head & Neck Surgery.2022; 74(S2): 2291.     CrossRef
  • Psychometric property of an instrument 1: content validity
    Eun-Hyun Lee
    Korean Journal of Women Health Nursing.2021; 27(1): 10.     CrossRef
  • Development of an Instrument to Assess the Nursing Professional Pride
    JaeHee Jeon, EunHee Lee, EunJoo Kim
    Journal of Korean Academy of Nursing.2020; 50(2): 228.     CrossRef
  • Reliability and Validity of the Arabic Version of the EORTC QLQ-C30 and QLQ-BR23 Questionnaires


    Ghufran Jassim, Ahmed AlAnsari
    Neuropsychiatric Disease and Treatment.2020; Volume 16: 3045.     CrossRef
  • Predictive Factors of Overall Well-Being Using the EORTC QLQ-C15-PAL Extracted from the EORTC QLQ-C30
    Kinsey Lam, Liang Zeng, Liying Zhang, Ling-Ming Tseng, Ming-Feng Hou, Alysa Fairchild, Vassilios Vassiliou, Reynaldo Jesus-Garcia, Mohamed A. Alm El-Din, Aswin Kumar, Fabien Forges PharmD, Wei-Chu Chie, Arjun Sahgal, Michael Poon, Edward Chow
    Journal of Palliative Medicine.2013; 16(4): 402.     CrossRef
  • Development and Validation of the Hospice Palliative Care Performance Scale
    So-Hi Kwon
    Journal of Korean Academy of Nursing.2011; 41(3): 374.     CrossRef
  • Translation and Validation of EORTC QLQ-C30 into Indonesian Version for Cancer Patients in Indonesia
    D. A. Perwitasari, J. Atthobari, I. Dwiprahasto, M. Hakimi, H. Gelderblom, H. Putter, J. W. R. Nortier, H.-J. Guchelaar, A. A. Kaptein
    Japanese Journal of Clinical Oncology.2011; 41(4): 519.     CrossRef
  • Psychometric Evaluation of a Need Scale for Cancer Patients Undergoing Follow-up Care
    Eun-Hyun Lee, Seongmi Moon, Soo-Yeon Cho, Young Taek Oh, Mison Chun, Sung Hwan Kim, Jae-Sung Kim, Hye Kyung Kim
    Journal of Korean Academy of Nursing.2010; 40(4): 551.     CrossRef
  • 17,858 View
  • 102 Download
  • 8 Crossref
Close layer
Development and Test of an Information Needs Scale for Outpatients Undergoing Chemotherapy
Eun Hyun Lee, Jin Hyuk Choi, Ho Yeong Lim, Mi Sook Seo, Hugh C Kim
Cancer Res Treat. 2002;34(2):97-103.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.97
AbstractAbstract PDF
PURPOSE
The purpose of this study was to develop and test an Information Needs Scale for Korean outpatients undergoing chemotherapy (INS-C).
MATERIALS AND METHODS
Thirty-three items of the INS-C had content validity based upon findings in the literature and the experiences of expert oncology physicians and nurses. Each item consisted of a five-point Likert scale from 1 (don't want to know) to 5 (want to know very much). The items were administered to 175 Korean outpatients undergoing chemotherapy. The data obtained was analysed using a factor analysis for construct validity and Cronabch's alpha for internal consistent reliability.
RESULTS
From the factor analysis, six subscales were derived significantly. The six subscales explained 64.62% of the variance. The subscales were named Side-Effects/Investigative Tests (9 items), Spread of Disease (4 items), Financial Cost (2 items), Treatment (7 items), Activities/ Eating (6 items), and Interrelationships/Support (5 items). The Cronbach's alpha of the total INS-C was .95, and the alpha of the subscales ranged from .77 to .91.
CONCLUSION
The present study suggests that the INS-C is a reliable and valid instrument to measure the information needs of outpatients undergoing chemotherapy. Health professionals caring for patients with cancer should assess the informational needs of their patients using a reliable and valid instrument and be prepared to provide accurate information.

Citations

Citations to this article as recorded by  
  • Psychometric Evaluation of a Need Scale for Cancer Patients Undergoing Follow-up Care
    Eun-Hyun Lee, Seongmi Moon, Soo-Yeon Cho, Young Taek Oh, Mison Chun, Sung Hwan Kim, Jae-Sung Kim, Hye Kyung Kim
    Journal of Korean Academy of Nursing.2010; 40(4): 551.     CrossRef
  • 3,472 View
  • 33 Download
  • 1 Crossref
Close layer
Intracavitary 166 Holmium - chitosan Complex Therapy in Patients with Malignant Peritoneal or Pleural Effusions
Do Yeun Cho, Hyun Soo Kim, Joon Seong Park, Cheol Kweon Jeong, Jin Hyuk Choi, Ho Yeong Lim, Chan Hee Park, Mi Son Chun, Young Mi Kim, Kyung Bae Park, Hugh Chul Kim
J Korean Cancer Assoc. 1999;31(6):1297-1306.
AbstractAbstract PDF
PURPOSE
Most malignant peritoneal or pleural effusions caused by advanced malignancy are unresponsive to systemic chemotherapy except for chemotherapy sensitive tumors, and they are equally ineffective to regional therapy or radiotherapy. Thus, for the purpose of palliating the symptoms related to malignant effusion and to reduce fluid reaccumulations, we evaluated the therapeutic feasibility and efficacy of intracavitary ' Ho-CHICO (chito- san complex) instillation for intractable malignant effusions.
MATERIALS AND METHODS
Thirty one patients with cytologically or pathologically proven malignant effusions underwent intracavitary 166Ho-CHICO therapy from May 1996 to March 1998 at Ajou University Hospital. The subjective and objective responses were evaluated 4 weeks after the treatment, including the changes of symptoms, weight, abdominal girth, doses of diuretics, frequencies and amounts of repeat aspirations for fluid reaccumulations, and imaging studies of chest radiograph and ultrasounds.
RESULTS
The response rates treated with Ho-CHICO were 50% in patients with peritoneal effusion and 46% in patients with pleural effusion (overall 49%). The response rates between 166Ho-CHICO doses of 50-80 mCi and 90-100 mCi were similar (50% vs 47%). Response rate of 70% was noted in patients with even distribution of radioisotope on the post-therapy scan, but, the response rate was lower in cases with focal (44%) and uneven (29%) distribution pattern. There was no difference in response by the effusion sites. All patients tolerated intracavitary 166Ho-CHICO instillation well, although the majority of patients experienced Grade I/II side effects such as pain, fever, weakness and dyspnea. But, no serious complications of Grade lII or IV degree were observed with 166Ho-CHICO therapy.
CONCLUSION
Intracavitary 166Ho-CHICO instillation was clinically efficacious in controlling malignant effusions without a significant toxicity seen with conventional sclerotic therapy. The therapeutic modality appeared to offer similar benefits obtained with the conventional intracavitary therapy.
  • 2,772 View
  • 14 Download
Close layer
Intrapleural instillation of OK-432 for malignant pleural effusion
Ho Yeong Lim, Joo Hang Kim, Young Hwan Park, Hyun Cheol Chung, Joung Ju Choi, Seoung Goo Choi, Ho Geun Kim, Jin Hyuk Choi, Nae Chun Yoo, Eun Hee Koh, Joon Chang, Jae Kyung Roh
J Korean Cancer Assoc. 1992;24(1):47-55.
AbstractAbstract PDF
No abstract available.
  • 2,709 View
  • 14 Download
Close layer
A clinical study of leiomyosarcoma of gastrointestinal tract
Hwa Young Lee, Jae Kyung Roh, Hyun Cheol Chung, Dong Lip Kim, Ho Yeong Lim, Eun Hee Koh, Joo Hang Kim, Hoon Sang Chi, Byung Soo Kim
J Korean Cancer Assoc. 1991;23(3):606-618.
AbstractAbstract PDF
No abstract available.
  • 2,557 View
  • 15 Download
Close layer
5-fluorouracil and low dose leucovorin in advanced colorectal carcinoma
Ho Yeong Lim, Hyun Cheol Chung, Jin Hyuk Choi, Nae Chun Yoo, Dong Lip Kim, Eun Hee Koh, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim
J Korean Cancer Assoc. 1991;23(3):563-570.
AbstractAbstract PDF
No abstract available.
  • 2,678 View
  • 14 Download
Close layer
Identification of Number of Positive Axillary Nodes to Influence Prognosis in Breast Cancer after Adjuvant CMF Chemotherapy
Ho Yeong Lim, Hyo Min Yoo, Eun Hee Koh, Nae Chun Yoo, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim, Kyung Shik Lee, In Sung Cho
J Korean Cancer Assoc. 1994;26(2):236-242.
AbstractAbstract PDF
The most important prognostic indicator for patients with operable breast cancer is the histological involvement of axillary lymph nodes metastasis, and the extent of nodal metastasis is highly prognostic, larger numbers of positive nodes are associated poorer prognosis. One hundred and nine patients of resected breast cancer with nodal involvement treated at Yonsei University College of Medicine from Dec. 1980 to Dec. 19S9 weres studied to identify the number of positive axillary nodes to influence prognosis after adjuvant CMF chemotherapy. And we obtained the following results. There was no significant difference in the disease free survival and overall survival between those with 1-3 positive axillary nodes and those with 4-7 positive nodes. So, we tried to reas- sess positive nodal groupings for determining the prognosis of breast cancer and identifying high risk group according to their nodal status. The current results showed that there was a significant difference in the disease free survival and overall survival between those with 1-7 positive axillary nodes and those with >= 8 positive nodes(DFS; 73% vs. 42%, OS; 78% vs. 40%, p < 0.05). This resport emphasizes the prognostic importance of positive nodal involvement with pa- tients of breast cancer and necessity of intensive managment for those with >= 8 positive nodes.
  • 2,894 View
  • 14 Download
Close layer
Induction Chemotherapy and Surgery in Locally Advanced Stomach Cancer Showing Pancreas Involvement
Kyung Hee Lee, Jin Hyuk Choi, Sun Young Rha, Hye Ran Lee, Nae Chun Yoo, Ho Yeong Lim, Hyun Cheol Chung, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim
J Korean Cancer Assoc. 1994;26(3):377-385.
AbstractAbstract PDF
Gastric cancer is the most common malignancy in Korea. Cure for patients with gastric carcinoma can be achieved only by radical surgery. From August 1988 to May 1992, 25 patients with locally advanced unresectable gastric cancer received 5-FU(Fiuorouracil) + adriamydn + mitomycin-c or 5-FU + cisplatin based induction chemotherapy before surgem. The partial response rate after me- dian 3 cycles of induction cemotherapy was 52%, stable disease 12%, progressive disease 36%. Gastric resection was performed in 18 patients(72%); 13 patients(52%) underwent radical surgery and 5 patients(20%) underwent palliative surgery. Median survival of the patients who underwent cura- tive and palliative surgery was 24. 2 and 27 months, respectively. However, median survival of the patient who didnt undergo any surgery was only 6.5 months. The difference of median survival between curative surgery and none surgery group were significant statistically(P<0.03). Side effects of induction chemotherapy were acceptable and there were no life threatening toxicities In this study, half of the patients can undergo curative surgery after induction chemotherapy. We observe the long term survival in some patients after induction chemotherapy and surgery in loco-regionally advanced gsstric cancer. This therapeutic approch for the locally advanced stomach cancer seems to be feasible. But, prospective tandomized clinical trial is warranted in the future.
  • 2,760 View
  • 14 Download
Close layer
Prognostic Significance of Proliferating Cell Nuclear Antigen ( PCNA
Ho Yeong Lim, Joo Hang Kim, Hyun Cheol Chung, Hyo Dong Um, Jin Hyuk Choi, Byung Soo Kim, Dong Hwan Shin, Jae Kyung Roh, Byung Soo Kim
J Korean Cancer Assoc. 1995;27(1):18-28.
AbstractAbstract PDF
Proliferatina cell nuclear antigen(PCNA) is known to be closely correlated with DNA synthesis and cell proliferation. Proliferative activities of tumors have recently been consid- ered as one of important prognostic factors in a variety of human cancers. A total of 195 gastric carcinomas was evaluated with immunohistochemical study, using an- tibody(PC 10) with special reference to the correlation between PCNA expression and progno- sis. PCNA expression was assessed semi-quantitatively based on the proportion of tumor cells with immunostained nuclei. There was no significant correlation between PCNA expression and clinicopathological variables such as age, sex, tumor site, size, histologic grade, tumor stage, or the presence of lymph node metastases. To analyse survival, we evaluated disease-free survival and overall survival according to the extent of PCNA expression. No significant correlations between PCNA expression and both disease-free survival and overall survival were found. In conclusion, PCNA expression assessed by semi-quantitative PCNA grading system was not a significant prognostic factor in gastric carcinoma.
  • 2,695 View
  • 13 Download
Close layer
Prognostic Factors in Node - Negative Breast Cancer
Kyung Hee Lee, Hyun Cheol Chung, Jae Yong Cho, Sun Young Rha, Joong Bae Ahn, Chong In Lee, Nae Choon Yoo, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim, Kyung Sik Lee, Kyl Beom Lee, Ho Yeong Lim, Jin Hy
J Korean Cancer Assoc. 1995;27(2):265-275.
AbstractAbstract PDF
Breast cancer is the third most common malignant neoplasm in Korean women. The effect of postoperative adjuvant systemic therapy in the treatment of primary breast cancer with pathologic involvement of the axillary lymph nodes has been well established. But, 20 30% of node-negative breast cancer patients will develop recurrent disease and risk death within 10 years after initial local therapy without adjuvant treatment. Therfore, it is reasonable to identify those node-negative breast cancer patients at significant risk for recurrence and who could be treated with adjuvant therapies. A clinical study was perofrmed in 184 cases of primary node-negative breast cancers from January 198l to December 1991 to study the natural course of the diaease and to find-out the prognostic factors. The following results were obtained; l) During 73 monthe(9-143) of follow-up duration, 5-year and 10-year relapse free survival rates were 88%, 77% respectively, and overall survival rates were 89%, 88%, respectively. 10 year recurrence rate was 19%. 2) Median disease-free and survival durations were 80 month, 17 months, respectively, in tumor size<2 cm group and 68.5 months, 62 months respectively in tumor size 2-5 cm group. 3) Median disease-free and overall survival durations were 73 months, 61 months, respectively, in premenopause patients and 74 months, 73 months in postmenopause patients. 4) No differences were found in disease-free and survival duration based on types of operation. 5) With adjuvant treatment, there was a decreasing tendency of systemic relapse. In conclusion, continuous relapse was found in node-negative breast cancer even after 5 years of operation. Even if decreasing tendency of systemic relapse was induced with adjuvant treatment, no clinically useful prognostic factors were found from surgical and pathologic factors until now. Further study of biological factors in node-negative breast cancer is warrented.
  • 3,314 View
  • 14 Download
Close layer
A Phase 2 Clinical Trial of Recombinant Human Granulocyte Macrophage Colony Stimulatin
Sun Young Rha, Jae Kyung Roh, Kyung Hee Lee, Hyun Cheol Chung, Jong Inn Lee, Jin Hyuk Choi, Hye Ran Lee, Nae Chun Yoo, Joo Hang Kim, Dae Seog Heo, Jin Hyuk Choi, Ho Yeong Lim, Jee Sook Hahn, Byung So
J Korean Cancer Assoc. 1995;27(3):490-504.
AbstractAbstract PDF
Background
; Rh GM-CSF is known to stimulate the growth of granulocyte-macrophage pre- cursors and can prevent the neutropenia and infection after high dose chemotherapy. We planned to evaluate the efficacy and toxicities of rh GM-CSF and to determine the clinically recommended dose of yeast-derived rh GM-CSF(LBD-005), based on the biologicaily active doses from phase I clinical triaL Methods; Open non-randomized phase II study was carried out in 40 cancer patients with chemotherapy induced myelosuppression. After the control period(chemotherapy without rh GM-CSF), rh GM-CSF was started 24 hours after the second chemotherapy to 3 groups of patients with the doses of 150, 250, 350 ug/m(2)/d by once-daily subcutaneous admlnistration for 10 days. Resnlts; Of the 40 enrolled patients, two patients refused to be followed and. one patient couldn't finish the study due to the disease progression. So 37 patients were evaluable and the number of patients at the dose of 150, 250, 350 pg/m/d were 12, 12 and 13 petients, respectively. They were consisted of 12 with stomach cancers, 10 with breast cancers, 5 with osteosarcoma and 10 patients with other malignancies, and received chemotherapeutic agents like VP-16, cisplatinum, adriamycin. When we compared the hematologic parameters between the control and treatment periods, the mean nadir of WBC counts(/mm(3)) at the dose of 150ug/m(2)/d were 1480, 2085, each, l280, l997 at the dose of 250 ug/m/d, and 1091, 1788 at the dose of 350 ug/m(2)/d respectively. Also the recovery days of WBC counts from nadir to 4000/m(3) were improved from 8 days in control period to 4.7 days in treatment period at the dose of 150 ug/m(2)/d. There were the same results at the dose of 250 and 350 ug/m(2)/d, such as from 7.4 days to 4.4 days and from 8.5 days to 5.2 days, respectively. In view of neutrophils, we could find the same results(p<0.05). There are trends that the recovery from nadir at the dose of 250 ug/m(2)/d or more is rapid, rather than l50ug/m(2)/d. Two patients with 350ug/m(2)/d complained of severe (WHO toxicity grade III) skin reaction and chest tightness, but they tolerated well after reduction to 250 ug/m(2) /d dose. Conclasion; This study suggested the effects of yeast-derived rh GM-CSF with the dose of 1SO, 250, 350ug/m(2)/d, S.Q. for 10 days to prvent the chemotherapy induced neutropenia. And when we considered the efficacy and tolerability, 250 ug/m(2)/d is appropriate for phase III clinical triaL
  • 2,910 View
  • 13 Download
Close layer
Expression in Matrix - Metalloproteinases ( MMP-2 , MMP-9 ) in Gastric Cancer as new Targets for Biotherapy
Hyun Cheol Chung, Jae Yong cho, Sun Young Rha, Joon Oh Park, Joong Bae Ahn, Choong In Lee, Nae Choon Yoo, Joo Hang Kim, Jae Kyung Roh, Sung Hoon Noh, Jin Sik Min, Byung Soo Kim, Ho Yeong Lim, Jin Hyu Choi
J Korean Cancer Assoc. 1995;27(6):897-907.
AbstractAbstract PDF
The proteolytic processes are thought to be the critical point in tumor invasion and metastasis, mainly by matrix-metalloproteinases (MMPs) and serine proteases. We measured the activities of MMP-9 and MMP-2 in the 120 normal and cancer tissue samples from the same patients using gelatin zymography. Inactive MMP-9(92 kD) was expressed in 73.3% of the normal and 87.5% of the cancer tissues, respectively (p=0.009), while active MMP-9(82 kD) was expressed in 24.2% and 53.3%, respectively (p=0.0001). Inactive MMP-2 (72kD) was expressed in 33.3% of the normal and 55.0% of the cancer tissues, respectively (p=0.001), while active MMP-2(62kD) was expressed in 4.2% and 31.7%, respectively (p=0.0001). In Tl state, only frequency of expression and enzymatic activity of the active MMP-2(62kD) were increased, while from T2 stage, the expression and the activation of the both MMP-9 and MMP-2 were increased as the cancer progressed. The expression frequency of the MMP-9 was more common than of the MMP-2. The co-expression rate of the active forms (82 kD, 62 kD), activites of 82 kD and 62 kD, and the activation rates of the both MMPs were increased as the cancer invades and metastasizes to distant lymph node areas. In conclusion, MMP-2 activation was the main causes of the increased MMPs activity during the Tl phase of the gastric cancer, while production and activation of the both MMP-9 and MMP-2 were increased as the cancer progressed. Therefore, we suggest that the different expression and activation of the MMPs in the gastric cancer progression can be a potential therapeutic target in gastric cancer biotherapy.
  • 4,010 View
  • 56 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP